WO1993022680A1 - Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces - Google Patents

Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces Download PDF

Info

Publication number
WO1993022680A1
WO1993022680A1 PCT/US1993/003767 US9303767W WO9322680A1 WO 1993022680 A1 WO1993022680 A1 WO 1993022680A1 US 9303767 W US9303767 W US 9303767W WO 9322680 A1 WO9322680 A1 WO 9322680A1
Authority
WO
WIPO (PCT)
Prior art keywords
ligands
group
thiol
groups
slides
Prior art date
Application number
PCT/US1993/003767
Other languages
French (fr)
Inventor
Glenn H. Mcgall
Stephen P. A. Fodor
Edward L. Sheldon
Original Assignee
Affymax Technologies N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Technologies N.V. filed Critical Affymax Technologies N.V.
Publication of WO1993022680A1 publication Critical patent/WO1993022680A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/045General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers using devices to improve synthesis, e.g. reactors, special vessels
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00364Pipettes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00364Pipettes
    • B01J2219/00367Pipettes capillary
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00364Pipettes
    • B01J2219/00367Pipettes capillary
    • B01J2219/00369Pipettes capillary in multiple or parallel arrangements
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00378Piezo-electric or ink jet dispensers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00389Feeding through valves
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00414Means for dispensing and evacuation of reagents using suction
    • B01J2219/00416Vacuum
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00427Means for dispensing and evacuation of reagents using masks
    • B01J2219/0043Means for dispensing and evacuation of reagents using masks for direct application of reagents, e.g. through openings in a shutter
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00427Means for dispensing and evacuation of reagents using masks
    • B01J2219/00432Photolithographic masks
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00457Dispensing or evacuation of the solid phase support
    • B01J2219/00475Sheets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/005Beads
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • B01J2219/00529DNA chips
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • B01J2219/00531Sheets essentially square
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • B01J2219/00536Sheets in the shape of disks
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00585Parallel processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/0059Sequential processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00596Solid-phase processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00608DNA chips
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/0061The surface being organic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00612Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623Immobilisation or binding
    • B01J2219/00626Covalent
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623Immobilisation or binding
    • B01J2219/0063Other, e.g. van der Waals forces, hydrogen bonding
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00659Two-dimensional arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068Means for controlling the apparatus of the process
    • B01J2219/00686Automatic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00709Type of synthesis
    • B01J2219/00711Light-directed synthesis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00722Nucleotides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00725Peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11Compounds covalently bound to a solid support
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/816Attached to the carrier via a bridging agent

Definitions

  • the present invention relates generally to methods and compositions useful for synthesizing and immobilizing oligonucleotides and other biological polymers on surfaces.
  • the immobilized biological polymers which can be, for example, oligonucleotides or polypeptides, are useful in a variety of screening and assay methodologies.
  • the present invention has applications in the fields of molecular biology, biochemistry, pharmacology, and medical diagnostic technology.
  • U.S. Patent No. 4,562,157 describes a technique for attaching biochemical ligands to surfaces by attachment to a photochemically reactive arylazide. Irradiation of the azide creates a reactive nitrene that reacts irreversibly with macromolecules in solution resulting in the formation of a covalent bond. The high reactivity of the nitrene intermediate, however, results in both low coupling efficiencies and many potentially unwanted products due to nonspecific reactions.
  • 4,681,870 describes a method for introducing free amino or carboxyl groups onto a silica matrix; the groups may subsequently be covalently linked to a protein in the presence of a carbodiimide.
  • U.S. Patent No. 4,762,881 describes a method for attaching a polypeptide chain to a solid substrate by incorporating a light-sensitive unnatural amino acid group into the polypeptide chain and exposing the product to low-energy ultraviolet light.
  • U.S. Patent No. 4,542,102 describes a method employing a photochemically active reagent (e.g., a psoralen compound) and a coupling agent, which attaches the photoreagent to the substrate. Photoactivation of the photoreagent binds a nucleic acid sequence to the substrate to five a sur ace-bound probe for a complementary oligonucleotide.
  • a photochemically active reagent e.g., a psoralen compound
  • a coupling agent which attaches the photoreagent to the substrate.
  • Photoactivation of the photoreagent binds a nucleic acid sequence to the substrate to five a sur ace-bound probe for a complementary oligonucleotide.
  • this method has low quantum yields in protic solvents, lacks spatial directability, and relies upon initial affinity between the photoreagent and nucleic acids to bind the nucleic acids to the surface prior to photoactivation.
  • U.S. Patent No. 4,937,188 describes methods for forming maleimide-thiol linkages between a solid support and a molecular tether *
  • thiol groups on sepharose are reacted with malei ide groups on an RNA polymer, which serves as the tether, and the RNA polymer is reacted with a protein, also via a maleimide-thiol linkage.
  • maleimide groups immobilized on a solid support are reacted with sulfhydryl RNAse forming RNAse-agarose.
  • 5,011,770 describes the use of a maleimide-thiol linkage to bind an -enzyme label to a binding protein, which in turn binds to single stranded DNA.
  • the patent describes that the binding protein can also be attached to a solid support.
  • the maleimide-thiol linkage is thus spatially separated from the actual linkage between the peptide and the solid support.
  • PCT patent publication No. 90/07582 describes polyacrylamide supports on which are immobilized oligonucleotides. The oligonucleotides are derivatized at the 5'-terminus with thiol groups that are reacted with bromoacetyl groups on the polyacrylamide support during the immobilization process.
  • 91/00868 discloses solid supports on which oligonucleotides are immobilized via a 5'- dithio linkage.
  • the immobilization of biological polymers on solid supports has also had significant impact on drug discovery and medical diagnostic methods.
  • One important invention in these fields is described in U.S. Patent No. 5,143,854, and the continuations-in-part of that application, Serial No. 624,120, filed December 6, 1990, and Serial No. 805,727, filed December 6, 1991, and in PCT patent publication Nos. 90/15070 to Pirrung et al. and 92/10092 to Fodor et al. , each of which is incorporated herein by reference.
  • Novel methods and compositions of matter are provided for synthesizing and immobilizing oligonucleotides and other biological polymers on predefined regions of a surface of a soiid support.
  • the methods involve attaching to the surface a thiol functional group protected with a photochemical protecting group so that the thiol has very low reactivity for other functional groups reactive with thiols.
  • the protected thiol is convertible by irradiation .o a fully reactive thiol capable of immobilizing a desired biological polymer such as a nucleic acid, protein, polysaccharide, or a monomer building block for such polymers.
  • Predefined regions of the surface are selectively irradiated to convert the protected thiols in the predefined regions to reactive thiol groups.
  • the desired biological polymers (or monomer) subsequently can be immobilized on the activated regions of the surface.
  • the spatial- addressability afforded by the method of the present invention allows the formation of patterned surfaces having preselected reactivities. For example, by using lithographic techniques known in the semiconductor industry, light can be directed to relatively small and precisely known locations on the surface. Thus, the present invention can be used to activate discrete, predetermined locations on the surface for attachment of biological polymers. The resulting surface will have a variety of uses. For example, direct binding assays can be performed in which nucleic acids in a sample can be simultaneously tested for affinity to a number of different oligonucleotide probes attached to the surface. Binding can be detected by a technique such as autoradiography when one of the binding moieties is radioactively labelled. Alternatively, fluorescence and optical measuring techniques can be used to detect the binding. By determining the locations and amount of label on the surface, one can simultaneously screen ligands for affinity to a plurality of anti-ligands.
  • the present invention provides methods for building arrays of biomolecules using photolithographic techniques.
  • the method obviates the need to separate reactants spatially, because the substrate is unreactive until specific sites are activated with light.
  • the method involves the light-directed immobilization of oligonucleotides on a glass surface derivatized with a caged thiol reagent. The method can be used to fabricate large arrays of oligonucleotide probes.
  • FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide; the results show that oligonucleotides activated with succinimidyl 6- maleimidylhexanoate are preferred for coupling to the thiol group-containing solid supports of the present invention (see Example 3) .
  • FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide; the results show that oligonucleotides activated with succinimidyl 6- maleimidylhexanoate are preferred for coupling to the thiol group-containing solid supports of the present invention (see Example 3) .
  • FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligon
  • “Surface” is any generally two-dimensional structure on a solid substrate and may have steps, ridges, kinks, terraces, and the like without ceasing to be a surface.
  • Predefined Region is a localized area on a surface which is or is intended to be activated.
  • the predefined region may have any convenient shape, e.g. , circular, rectangular, elliptical, etc.
  • Crosslinking Group is a bifunctional chemical entity that serves to connect a binding member to a surface. Usually, crosslinking groups are heterobifunctional and so have different chemical reactivities on either end of the linking group.
  • Biological Polymer is a compound composed of monomeric units linked to one another that has biological activity or is reactive with a compound that has biological activity. Nucleic acids such as RNA and DNA are biological polymers, and peptides, proteins, and carbohydrates are also biological polymers.
  • Anti-ligand is a molecule or a complex of molecules that has an affinity for a given ligand and can be immobilized on a predefined region of a surface. Anti-ligands may be naturally-occurring or synthetic molecules. Anti-ligands can be employed in an unaltered state or as aggregates with other species. Anti-ligands can be reversibly attached, covalently or noncovalently, to a. binding member, either directly or via a specific binding substance.
  • Reversibly attached means that the binding of the anti-ligand (or specific binding member or ligand) is reversible and has, therefore, a substantially non ⁇ zero reverse, or unbinding, rate.
  • reversible attachments can arise from noncovalent interactions, such as electrostatic forces, van der Waals forces, hydrophobic (i.e., entropic) forces-, and the like.
  • reversible attachments also may arise from certain, but not all, covalent bonding reactions. Examples include, but are not limited to, attachment by the formation of hemiacetals, hemiketals, imines, acetals, ketals, and the like (See, Morrison et al. , "Organic Chemistry” , 2nd ed.
  • anti-ligands examples include, but are not restricted to, receptors, such as cell membrane (such as those of B-cells, T-cells, and macrophages) receptors, polyclonal and monoclonal antibodi-es, and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials) , hormones, drugs, oligonucleotides, peptides, enzymes, lectins, sugars, oligosaccharides, cells, cellular membranes, cellular membrane transport proteins, and organelles.
  • receptors such as cell membrane (such as those of B-cells, T-cells, and macrophages) receptors, polyclonal and monoclonal antibodi-es, and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials) , hormones, drugs, oligonucleotides, peptides, enzymes, lectins, sugars, oligosaccharides,
  • Ligand is a solvated molecule that is recognized by a particular anti-ligand.
  • ligands that can be investigated with the present invention include, but are not restricted to, agonists and antagonists for cell membrane receptors, toxins and venoms, antigenic determinants, such as viral epitopes, hormones, opiates, steroids, peptides, enzyme substrates, cofactors, drugs, lectins, sugars, oligonucleotides, oligosaccharides, and proteins.
  • the present invention provides methods for forming predefined regions on a surface of a solid support, wherein the predefined regions comprise caged thiol groups that can be activated and then used to immobilize ligands and/or anti- ligands.
  • the caged thiols attached to the surface can be selectively activated in predefined regions via covalent linkages.
  • the activated thiols are then used to immobilize compounds, e.g., anti-ligands, on the predefined regions of the surface.
  • the above procedure can be repeated at the same or different sites on the surface so as to provide a surface with a plurality of regions containing the same or different ligands or anti-ligands.
  • screenings and assays for the ligands can be conducted in the regions of the surface containing the anti-ligands.
  • the present method employs novel caged thiols attached to the substrate.
  • Caged (unactivated) thiols have relatively low reactivity with functional groups typically reactive with thiols when compared with uncaged thiols.
  • the caged thiols are protected until a suitable source of energy is applied to the regions of the surface to be activated.
  • the caging groups labilize, thereby presenting the thiol.
  • the energy source will -be light.
  • the thiol groups on the surface Prior to activation, however, the thiol groups on the surface are "caged" with a protecting group.
  • the protecting groups can either be attached to the compounds carrying the thiol functional group after those compounds have been attached to the surface or, more preferably, the protecting groups will be attached to the compounds carrying the thiol functional group prior to attaching the thiol functional group to the surface.
  • Surface attachment of compounds carrying a thiol group or protected thiol group can be effected through the use of crosslinking groups.
  • the crosslinking groups will usually, though not always, be- heterobifunctional chemical species having- a first reactivity that permits the crosslinking group to bind readily to the surface and a second reactivity that permits the crosslinking group to -bind- readily with compounds carrying a thiol group or protected thiol group.
  • predefined regions on the surface can be activated for ultimate immobilization of anti-ligands in the predefined regions by selectively irradiating predefined regions to convert photoactivatable thiol groups in the predefined region to fully reactive thiol groups.
  • the free protecting group may or may not undergo decomposition reactions.
  • the byproducts of irradiation of the protecting group will usually be washed from the surface if the byproducts interfere with subsequent reactions.
  • An immobilized anti-ligand on a surface will have a specific binding affinity for a particular ligand. If a surface comprising immobilized anti-ligands is exposed to a labeled ligand under conditions conducive to ligand binding to anti-ligand, then the resulting surface can be washed free of unbound ligand and analyzed for the presence of labeled ligand.
  • the labels will provide markers localized at the predefined regions on the surface corresponding to the presence of anti- ligands for the ligand at those predefined regions.
  • the presence of target ligand can be determined by analyzing appropriately for the loss or buildup of label on the predefined regions of the surface.
  • a substrate for surface modification can be employed in the method of the invention.
  • the substrate can be biological, nonbiological, organic, inorganic, or a combination of any of these materials, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, -pads, slices, films, plates, slides, etc.
  • the substrate can have any convenient shape, such as a disc, square, sphere, circle, etc.
  • the substrate and the surface of the substrate preferably form a rigid support on which to carry out the reactions described herein.
  • the substrate and the surface should also be chosen to provide appropriate light-absorbing characteristics.
  • the substrate can be a polymerized Langmuir Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, Si0 2 , SiN 4 , modified silicon, or any one of a wide variety of polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, or combinations thereof.
  • Other substrate materials will be readily apparent to those of skill in the art upon review of this disclosure.
  • the substrate is flat glass or single-crystal silicon with surface features of less than 10 angstroms. Surfaces on the solid substrate will usually, though not always, be composed of the same material as the substrate.
  • the surface may be composed of any of a wide variety of materials, for example, polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, membranes, etc., provided only that caged thiols can be attached to the surface of the substrate.
  • the surface will contain reactive groups, which could be carboxyl, amino, hydroxyl, or the like.
  • the surface will be optically transparent and will have surface Si-OH functionalities, such as are found on silica surfaces.
  • the surface of the substrate is preferably provided with a layer of crosslinking groups, although one of ordinary skill will understand that the crosslinking groups are not required elements of the invention.
  • the crosslinking groups are preferably of sufficient length to permit thiol groups on the surface, as well as biological polymers covalently attached to the thiol groups, to interact freely with compounds in solution.
  • Crosslinking groups can be selected from any suitable class of compounds, for example, aryl acetylenes, ethylene glycol oligomers containing two to ten monomer units, dia ines, diacids, amino acids, or combinations thereof. Other crosslinking groups may be used in view of this disclosure.
  • Crosslinking groups can be attached to the surface by a variety of methods that are readily apparent to one having skill in the art. For example, crosslinking groups may be attached to the surface by siloxane bonds formed via reactions of crosslinking groups bearing trichlorosilyl or trisalkoxy groups with hydroxyl groups on the surface of the substrate.
  • the crosslinking group used with a glass surface is t-BOC-aminopropyltriethoxysilane.
  • the crosslinking groups can optionally be attached in an ordered array, i.e., as parts of the head groups in a polymerized Langmuir Blodgett film.
  • the type of crosslinking group selected, and the method selected for attaching the crosslinking group to the surface will depend primarily on the crosslinking group having suitable reactivity with the compound carrying the thiol group desired to be attached to the surface.
  • linking groups are preferably heterobifunctional, having one end adapted to react with the crosslinking groups and the other end adapted to react with the compound carrying the thiol group or another linking group.
  • the linking groups may be attached by a variety of methods that are readily apparent to one skilled in the art, for instance, by esterification or amidation reactions of an activated ester of the linking group with a reactive hydroxyl or amine on the free end of the crosslinking group.
  • a preferred linking group is N-BOC-6- aminocaproic acid (or N-BOC-6-aminohexanoic acid) attached by the BOP-activated ester. After deprotection to liberate the free amine terminus, another N-BOC-aminocaproic linker can be added. Attachment of crosslinking and linking groups to caged thiol compounds are discussed more fully below.
  • the compound carrying the thiol group can be linked to the surface and later provided with protecting (caging) groups. More preferably, compounds carrying the thiol group will be attached to the surface in a protected form.
  • the method chosen for linking the compound carrying the thiol group to the surface will depend upon the chemical properties of the compound carrying the thiol group selected for attachment to the surface.
  • a preferred method for immobilizing the compound carrying the thiol group of the present invention involves chemical derivatization or activation of the caged compound carrying the thiol group prior to attachment to the surface or linker.
  • This derivative or activated species is then reacted with functionalities on the substrate to give the desired linkage.
  • a bifunctional crosslinking reagent such as diepoxide, which both activates the surface and provides a group that reacts with an activated compound carrying the thiol group.
  • some surfaces can be activated with cyanogen bromide.
  • an amine group on the surface can be coupled to a carboxyl group of a compound carrying the thiol group to effect the immobilization.
  • the compound carrying the thiol group is a caged cysteine, or other thiol-containing synthetic or natural amino acid.
  • Such compounds are useful in a wide variety of applications; for instance, one could carry out amino acid addition on either the amino or carboxyl groups of the protected cysteine and then, after photoactivation, derivatize the side chain of the cysteine residue.
  • Such techniques will often employ different classes of protecting groups, so that one can modify the immobilized molecules at different reactive groups. These techniques include cyclization, where the cyclization step is controlled by the use of protecting groups on the two amino acid residues undergoing cyclization that are different from the protecting groups on amino acid residues that are not to be cyclized. See U.S. patent application Serial Nos. 796,727, filed November 22, 1991, and 946,239, filed September 16, 1992, each of which is incorporated herein by reference.
  • protecting (caging) groups can be employed for modifying thiol groups to give the caged thiols of the present invention.
  • the protecting groups should be sterically large enough to reduce the reactivity of the caged thiol with other substances to permit operability of the invention, although protecting groups utilizing other types of interactions, such as electronic, hydrophobic, etc., could be used.
  • the selection of suitable caging groups will depend upon the size and chemical nature of the compound carrying the thiol group chosen and will- be readily apparent to one skilled in the art.
  • the caging groups are photoactivatable. The properties and uses of photoreactive caged compounds have been reviewed. See McCray et al. , 1989, Ann. Rev. Biophvs. Biophys. Chem.
  • the photosensitive cages will be activatable by low energy ultraviolet or visible light.
  • the photosensitive protecting groups are aromatic compounds. Suitable photoremovable protecting groups are also described in, for example, Patchornik, 1970, J. Am- Chem. Soc. 92:6333. and Amit et al. , 1974, J. Orq. Chem. 3_9_:192, which are incorporated herein by reference. See also, Calbiochem Catalog (San Diego, CA, 1989), pp. 244-247, incorporated herein by reference.
  • the photosensitive protecting group will be a nitro benzylic compound, such as o-nitrobenzyl or benzylsulfonyl groups.
  • a nitro benzylic compound such as o-nitrobenzyl or benzylsulfonyl groups.
  • 6- nitroveratryloxycarbonyl (NVOC) ; 6-nitropiperonyloxycarbonyl (NPOC) ; alpha, alpha-dimethyldimethoxybenzyloxycarbonyl (DDZ) , methyl 6-nitroveratryloxycarbonyl (MenVOC) , methyl-6- nitropiperonyloxycarbonyl (MeNPOC) , or 1-pyrenylmethyl is employed.
  • photosensitive protecting groups are suitable for use in the present method.
  • Some examples of acceptable photosensitive protecting groups are presented in Table l, below, together with their corresponding wavelengths for deprotection.
  • NVOC 6-nitroveratryloxycarbonyl
  • DDZ dimethyldimethoxybenzyloxycarbonyl
  • NBOC nitrobenzyloxycarbonyl
  • the radiation is UV, near IR, or visible light.
  • the light source may be coherent or noncoherent.
  • the exposed area is less than about 1 cm 2 or less than about 1 mm 2 .
  • the irradiated area will be composed of a pattern of smaller, discrete irradiated areas, each of which is less than about 10,000 ⁇ m 2 or, more preferably, less than about 100 ⁇ m 2 .
  • each individual synthesis site in the pattern is about 50 to 500
  • Spaces between activated regions are not optional and, if used, will generally be greater than about 1 ⁇ m.
  • Exposure of the surface to light will typically be carried out with a suitable mask using photolithographic techniques well known in the semiconductor industry and described in, for example, Sze, VLSI Technology. McGraw-Hill (1983) , which is incorporated herein by reference. See U.S. Patent No. 5,143,854.
  • the mask is a transparent support material coated with a layer of opaque material (i.e., chrome- plated glass) . Portions of the opaque material are removed (or never deposited) , leaving a pattern that matches the precise pattern desired on the substrate surface.
  • the mask can be a sheet or film composed of a non-transparent substance (i.e., anodized aluminum) ,- which sheet or film has been perforated in the desired pattern.
  • the mask is brought into close proximity with or directly into contact with the surface. Openings -in the mask correspond to locations on the surface where one desires to photoremove protecting groups from thiol groups. Alignment may be performed using conventional alignment techniques in which alignment marks are used to overlay accurately successive masks with previous patterning steps. Other alignment techniques may be used, for example, interferometric techniques such as the one described in Flanders et al. , 1977, App. Phys. Lett. 3_l:426-428, which is incorporated herein by reference.
  • contrast enhancement materials between the mask and the substrate.
  • This contrast enhancement layer may comprise a molecule, such as -quinone diazide, which is decomposed by light.
  • the light may be from a conventional incandescent source, an arc lamp, a laser, or the like. If noncoherent sources of light are used, one may utilize a thick or multi-layered mask to prevent spreading of the light on the substrate.
  • lasers may be preferable, because lasers can more easily provide wavelengths particularly suited for a chromophore of the photosensitive group.
  • the substrate may be rotated or oriented under a modulated laser or diode light source. Such techniques are discussed in, for example, U.S. Patent No. 4,719,615, which is incorporated herein by reference.
  • the substrate may be irradiated either in contact with or not in contact with a solution but usually is irradiated in contact with a solution.
  • the solution may contain reagents to prevent byproducts of irradiation from interfering with subsequent binding reactions.
  • byproducts might include, for example, carbon dioxide, nitrosocarbonyl compounds, styrene derivatives, indole derivatives, and products of the photochemical reactions of such compounds.
  • Reagents added to the solution may include, for example, acidic or basic buffers, thiols, substituted hydrazines and hydroxylamines, reducing agents (e.g., NADH,
  • DTT dimethyl sulfoxide
  • a given functional group e.g., aryl nitroso plus glyoxylic acid aryl form hydroxamate plus C0 2
  • protecting groups will be selected that do not cause significant interference with the binding reactions.
  • wash steps can be incorporated so that the byproducts do not interfere with the reactions.
  • the light pattern can be changed and the same or a different anti- ligand, ligand, polymer, or monomer can be localized at other discrete sites on the- surface.
  • Anti-ligands that are nucleic acids are especially preferred.
  • a plurality of nucleic acid anti-ligands are immobilized on a surface by first attaching photoreactive caged thiols to the surface. The caged thiols on a predefined region of the surface are exposed to light to give reactive thiol groups.
  • the reactive thiol groups on the predefined region are then incubated with a first activated nucleic acid anti-ligand to be immobilized, the surface is washed free of unreacted nucleic acid, and the surface is incubated with a desired ligand.
  • the exact incubation conditions e.g., time, temperature, pH, etc., will depend upon the species used and will be readily apparent to one skilled in the art.
  • the above steps can be repeated on a different region of the surface with a different nucleic acid. In this fashion, a small, dense array of-, e.g., oligonucleotide probes, can be prepared.
  • a surface prepared according to the methods described above can be used to screen for ligands having high affinity for immobilized anti-ligands. Screening can be performed by immobilizing a plurality of anti-ligands on predefined regions of a surface by the methods described above. A solution containing a marked (labelled) ligand is introduced ' to the surface and incubated for a suitable period of time. The surface is then washed free of unbound ligand, and the anti- ligands having high affinity for the ligand are identified by identifying those regions on the surface where markers are located. Suitable markers include, but are not limited to, radiolabels, chromophores, fluorophores, chemiluminescent moieties, and transition metals.
  • the marker is a radioactive label, such as 32 P.
  • the marker on the surface is exposed to X-ray film, which is developed and read out on a scanner. An exposure time in the range of 1 to 24 hours is typical. Fluorescence detection using a fluorophore label, such as fluorescein, attached to the ligand will usually require much shorter exposure times.
  • the presence of ligands may be detected using a variety of other techniques, such as an assay with a labelled enzyme, antibody, or the like. Other techniques using various marker systems for detecting bound ligand will be readily apparent to those skilled in the art. See U.S. Patent No. 5,143,854.
  • a substrate prepared as discussed above can be exposed to a solution containing one or more ligands such as nucleic acids.
  • the ligand can be labeled in any of a variety of ways, but in one embodiment, the ligand is an oligonucleotide probe having a radioactive (or other) label.
  • the ligand nucleic acid binds (hybridizes) with high affinity to an immobilized nucleic acid previously localized on the surface and to the complementary labeled probe. Hybridization conditions are known in the art, but the arrays of the invention allow one to use very small volumes of target- containing solution for analysis.
  • micropipettes to deliver very small volumes (i.e., 1 to 5 ⁇ L or less) very precisely, one can allow evaporation to drive hybridization.
  • the surface is placed proximate to X-ray film, if a radioactive label is employed, to identify the nucleic acids on the surface complementary to the nucleic acid ligand.
  • a fluorescent label can be used, and detection can be accomplished with a charge-coupled device (CCD) , fluorescence microscopy, or laser scanning.
  • CCD charge-coupled device
  • fluorescence microscopy or laser scanning.
  • a related labeling technique involves the use of a labeled probe in solution that will hybridize with the target nucleic acid ligand without interferring with hybridization of the ligand to the immobilized probe.
  • the capture probes are designed to have a sequence complementary to the target sequence to be detected and a sequence complementary to an immobilized probe located at one or more discrete locations on the surface of the substrate.
  • either the capture probe is labeled or another labeled probe complementary to the target sequence to be detected is employed.
  • This system allows the hybridization of probe to target sequence to be carried out in solution, because the immobilized probe array does not have to be (but can be, if desired) present in the reaction mixture during hybridization of the capture probe to the target sequence.
  • Quantitative assays for ligand concentrations can also be performed according to the present invention.
  • a direct assay method the surface containing localized anti- ligands prepared as described above is incubated with a solution containing a labeled ligand for a suitable period of time. The surface is then washed free of unbound ligand. The amount of label present at predefined regions of the surface is then measured and can be related to the amount of ligand in solution.
  • Methods and conditions for performing such assays are well-known and are presented in, for example, Hood et al., Immunology (Benjamin/Cummings 1978) and Harlow et al..
  • a competitive assay method can also be employed using the methods and reagents of the present invention.
  • Such a method involves immobilizing anti-ligands on predefined regions of a surface as described above. An unmarked ligand is then bound to anti-ligands on the surface having specific binding affinity for the ligand. A solution containing marked ligand is then introduced to the surface and incubated for a suitable time. The surface is then washed free of unbound reagents, and the amount of marker remaining on the surface is measured.
  • marked and unmarked ligand can be exposed to the surface simultaneously.
  • the amount of marker remaining on predefined regions of the surface can be related to the amount of unknown ligand in solution.
  • the invention is illustrated in the Examples below primarily with reference to the identification of specific nucleic acid sequences in a sample. The invention will, however, find many other uses.
  • the invention can be used in information storage (e.g., on optical disks), production of molecular electronic devices, production of stationary phases in separation sciences, and in immobilization of- cells, proteins, lectins, nucleic acids, polysaccharides and the like in any desired pattern on a surface via molecular recognition of a specific anti-ligand linked via a thiol group to a surface of a substrate.
  • Example 1 Preparation of Substrate and Thiol-derivatized Surface A. Preparation of Substrate Surface
  • Commercially available glass microscope slides for example, 1" x 3" smooth cut, 0.7 mm thick, anti-scratch coated slides or 2" x 3" smooth cut, 0.7 -mm thick, anti-scratch coated slides from Erie Scientific
  • t-BOC- aminopropyltriethoxy silane in substantial accordance with the procedure described in J. Chromatography 97:33 (1974), incorporated herein by reference.
  • the slides were cleaned by soaking in 10% Micro detergent (Baxter) , individually scrubbed, and immersed in deionized water.
  • the slides were then subjected to a 10 minute sonication in a 70°C solution of 10% Micro detergent and rinsed ten times with deionized water. This process was followed by a three minute immersion in a 70°C solution of 10% (w/v) NaOH.
  • the slides were then rinsed ten times with deionized water, and then immersed for one minute in 1% HC1.
  • the slides were then again rinsed ten times with deionized water, and then subjected to another 10 minute sonication in 70°C deionized water, after which the slides were rinsed three to four times in deionized water.
  • the slides were then ethanol rinsed and dried with nitrogen or argon.
  • the slides were then inspected visually for spots and scratches in a yellow light with a black background, and any slides that were scratched- or spotted or that still retained the anti-scratch coating were either discarded or recleaned.
  • An alternate or additional cleaning procedure is carried out as follows.
  • the slides are loaded into teflon racks and subjected to a thirty minute immersion in a solution composed of Nochromix (Aldrich) with 36 g/L of concentrated sulfuric acid (which can be regenerated if discolored) that has been filtered (glass fiber filter) to remove particulate matter. Occasional agitation is provided during the thirty minute immersion step.
  • the slides are then rinsed for one minute in deionized water with vigorous agitation.
  • the slides are then placed for ten minutes in a rinse tank with 14 psi argon or nitrogen bubbling, a full open deionized water tap, and occasional agitation.
  • the slides are then immersed for three minutes in a 70°C solution of 10% (w/v) NaOH, followed by a one minute rinse with deionized water and vigorous agitation, followed by a ten minute rinse in a rinse tank.
  • the slides are then immersed for one minute in 1% HC1 and then rinsed for five minutes in a rinse tank.
  • the slides are then ethanol rinsed, dried with nitrogen or argon, and inspected visually for spots and scratches.
  • the t-BOC aminopropyl derivatization is carried out as follows.
  • the slides are loaded into plastic staining jars, with about nine slides per jar.
  • the slides are completely dry when placed in the staining jars, and the silation reagents are added as follows.
  • the silation reagent is a premixed solution of a 1:10 molar ratio of t-BOC- aminopropyltriethoxysilane:methyltriethoxysilane (i.e., 1 L of t-BOC-aminopropyltriethoxysilane and 5.86 mL of methyltriethoxysilane, which is kept anhydrous and stored under argon) .
  • the silation reagent is diluted to 1% (v/v) in dichloromethane (DCM) , mixed well, and 60 mL of the diluted silation reagent are added to each jar.
  • the jars are capped and incubated overnight at room temperature.
  • the slides are removed from the jar, rinsed first with DCM and then with toluene and then dried immediately with argon.
  • the slides are then loaded onto glass drying racks, inspected for streaks, and allowed to stand for approximately thirty minutes.
  • the slides are then baked for one hour in a 100°C oven with the glass racks in metal trays covered with foil. The oven should be no hotter than 110°C.
  • the slides are then cooled and optionally numbered with an engraving tool.
  • DIEA diisopropylethylamine
  • Nitroveratrylthiolpropionic acid was prepared in substantial accordance with the protocols set forth in Patchornik et al.. , 21 Oct. 1970, J. Am « Chem. Soc. 92(21) :6333- 6335, incorporated herein by reference.
  • the aqueous phase was separated, acidified with 1 N HC1, extracted with methylene chloride, and then the organic layer was dried (Na 2 S0 4 ) , and ihen rotary evaporated to dryness. About 0.54 g of nitroveratrylthiolpropionic acid was obtained.
  • the product can be further purified by dissolving the product in ethanol, adding five volumes of water, and collecting the needle-shaped crystals by filtration.
  • Example 2 Coupling of Fluorescein Maleimide to Substrate Surface
  • a glass microscope slide- prepared as described in Example IC was mounted on a flow cell and illuminated through a 500 ⁇ m 500 ⁇ m checkerboard-pattern mask (Photo Sciences Inc. , Torrance, CA) using broad-band UV/blue light. This pattern was repeated in triplicate on each slide, and the illumination was carried out so that one region underwent a four minute photolysis, a second region underwent a two minute hydrolysis, and a third region underwent a one minute photolysis.
  • a 500 ⁇ m 500 ⁇ m checkerboard-pattern mask Photo Sciences Inc. , Torrance, CA
  • the light source was a 500 W Mercury arc lamp (Oriel Model 87330) equipped with a 350 nm - 450 nm dichroic reflector that produced actinic light having an intensity of 12 mW/cm 2 as measured through a 360 nm bandpass filter.
  • the derivatized surface was photolyzed in flowing dioxane for 15 minutes and then rinsed in ethanol and dried with argon. About 4.3 mg of fluorescein maleimide (Molecular
  • Probe were dissolved in 10 mL of warm DMF to obtain a one mM solution of fluorescein maleimide. This solution was allowed to cool to room temperature, and then the slide was immersed in the solution and incubated at room temperature for two hours with gentle agitation. The slide was then removed from the solution and rinsed sequentially with DMF, ethanol, methylene chloride, and again with ethanol, and then the slide was dried with argon.
  • the slide was examined with a scanning fluorescence microscope (Zeiss Axioskop equipped with a Newport Model PM500- C motion controller, a Spectra-Physics Model 2020 argon-ion laser producing a 488 nm excitation light; and a 520 nm long- pass emission filter) interfaced with a photon-counting device (Hamamatsu Model 9403-02 photomultiplier; Stanford Research Systems Model SR445 amplifier and Model SR430 multichannel sealer, IBM compatible PC) to generate a two-dimensional image consisting of fluorescence intensity data as a function of x,y position.
  • a scanning fluorescence microscope Zeiss Axioskop equipped with a Newport Model PM500- C motion controller, a Spectra-Physics Model 2020 argon-ion laser producing a 488 nm excitation light; and a 520 nm long- pass emission filter
  • a photon-counting device Hamatsu Model 9403-02 photo
  • Example 3 Coupling of Oligonucleotides with Thiol-reactive Groups to Substrate Surface This example shows the results of a test for the effectiveness of several different thiol-reactive groups that, when attached to an oligonucleotide, enable covalent coupling to thiol-derivatized glass slides.
  • a 5*-fluoresceinated 3'-C6-amino oligonucleotide probe (designated CAP2, which was prepared using the Clonetech reagent 3*-C6-amino-modifier-CPG) was activated with the following heterobifunctional reagents: (1) succinimidyl bromoacetate (BrAc-NHS) ; (2) succinimidyl iodoacetate (IAc- NHS) ; (3) succinimidyl 6-( (iodoacetyl)amino)hexanoate (SIAX) ; (4) succinimidyl 6-(6-(( (iodoacetyl)amino)hexanoyl)amino)- hexanoate (SIAXX) ; and (5) succinimidyl 6-maleimidylhexanoate (EMCS) .
  • succinimidyl bromoacetate BrAc-NHS
  • the reaction was incubated at 25°C for 30 minutes, and the resulting modified oligonucleotide was desalted on a G-25 spin column (unbuffered water) and then used without further purification at a concentration of about 100 ⁇ M (determined spectrophotometrically) .
  • Polyacrylamide gel electrophoresis assays after quenching- with a fluorescent thiol indicated that about 75% of the oligonucleotides were modified in the.reaction.
  • This example shows the results of the addition of a variety of additives on the coupling efficiency of a maleimide- activated, 5'-fluoresceinated oligonucleotide to thiol- derivatized slides.
  • the 5*-fluoresceinated 3'—C6-amino oligonucleotide was activated with succinimidyl 6- maleimidylhexanoate and applied to a freshly photolyzed slide as a solution in water in substantial accordance with the procedure set forth in Example 3.
  • Example 5 Hybridization of Nucleic Acids to Immobilized Oligonucleotide
  • Two glass slides prepared in accordance with the procedures set forth in Examples 3 and 4 were tested for ability to hybridize specifically with a complementary oligonucleotide.
  • the two slides differed with respect to the additive present during the coupling reaction; one slide was coupled to oligonucleotide in the presence of LiCl, the other in the presence of DTAB.
  • the slides were prehybridized individually in heat sealed bags at 56°C with a solution composed of 6X SSC, 6X Denhardt's solution, 0.5% SDS, and 100 ⁇ g/mL of sheared, denatured, salmon sperm DNA.
  • the hybridization reaction was carried out at 53.5°C (T M minus 5°C) in prehybridization buffer containing 1 pmole of a 32 P-end labeled 60mer probe (specific activity of 1.5 x 10 8 CPM/ ⁇ g) containing a 30 nucleotide segment perfectly complementary to the covalently coupled oligonucleotide probe.
  • the hybridized slides were evaluated in a beta plate counter and by autoradiography.
  • hybridization acceleration reagents that can be employed in the method of the present invention include Al protein, RecA protein, SSB, dextran sulfate, ficoll, phenol, and detergent.
  • Prehybridization was carried out for 15 minutes at 53.5°C, and then 100 ⁇ L of 10 mg/mL salmon sperm DNA was added to the slides together with 10 ⁇ L (one pmole) of the labeled probe.
  • the hybridization reaction was carried out at 53.5°C for one hour.
  • the slides were washed and then allowed to expose XAR film overnight at -70°c.
  • Example 2 A slide prepared as described in Example 1 is photolyzed under dioxane and then rinsed with ethanol and dried under a nitrogen stream. The slide is clamped to a template that forms a well over the photolyzed area, and 20 ⁇ L of a 100 ⁇ M solution of 3•-EMCS-activated probe CAP2 ( ⁇ '-CCAACTCTTTTTCCGAAGGTAACTGGCTTC [SEQ. ID NO. 1]) in unbuffered water and HEPES/EDTA/DTAB buffer are added to the well.
  • 3•-EMCS-activated probe CAP2 ⁇ '-CCAACTCTTTTTCCGAAGGTAACTGGCTTC [SEQ. ID NO. 1]
  • the slide and template are then incubated at room temperature for two hours, the reaction is quenched by the addition of N-ethyl maleimide, and the slide is rinsed liberally first with water and then with dioxane. The slide is then re-photolyzed to activate a different region on the slide and then coupled to 3'-ECMS-activated probe CAP5 (5 1 -
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Abstract

Substrates with surfaces comprising compounds with thiol functional groups protected with a photoremovable protecting group can be used to construct arrays of immobilized anti-ligands, such as oligonucleotide probes or other biological polymers. The arrays can be used in assays to detect the presence of complementary nucleic acids in a sample. Spatially addressed irradiation of predefined regions on the surface permits immobilization of oligonucleotides and other biological polymers at the activated regions on the surface. Cycles of irradiation on different regions of the surface and immobilization of different anti-ligands allow formation of an immobilized matrix of anti-ligands at defined sites on the surface. The immobilized matrix of anti-ligands permits simultaneous screenings of a liquid sample for ligands having high affinities for certain anti-ligands of the matrix.

Description

SPATIALLY-ADDRESSABLE IMMOBILIZATION OF OLIGONUCLEOTIDES AND OTHER BIOLOGICAL POLYMERS ON SURFACES
BACKGROUND OF THE INVENTION Field of the Invention The present invention relates generally to methods and compositions useful for synthesizing and immobilizing oligonucleotides and other biological polymers on surfaces. The immobilized biological polymers, which can be, for example, oligonucleotides or polypeptides, are useful in a variety of screening and assay methodologies. The present invention has applications in the fields of molecular biology, biochemistry, pharmacology, and medical diagnostic technology.
Description of Related Art Many different methods are known for attaching biological molecules to solid supports. See generally, Affinity Techniques. Enzyme Purification: Part B, Meth. Enz. 34 (ed. W.B. Jakoby and M. ilchek, Acad. Press, NY 1974) and Immobilized Biochemicals and Affinity Chromatocrraphv, Adv. Exp. Med. Biol. 42 (ed. R. Dunlap, Plenum Press, NY 1974) , incorporated herein by reference. The patent literature also describes a number of different methods for attaching biological molecules to solid supports. For example, U.S. Patent No. 4,282,287 describes a method for modifying a polymer surface through the successive application of multiple layers of biotin, avidin, and extenders. U.S. Patent No. 4,562,157 describes a technique for attaching biochemical ligands to surfaces by attachment to a photochemically reactive arylazide. Irradiation of the azide creates a reactive nitrene that reacts irreversibly with macromolecules in solution resulting in the formation of a covalent bond. The high reactivity of the nitrene intermediate, however, results in both low coupling efficiencies and many potentially unwanted products due to nonspecific reactions. U.S. Patent No. 4,681,870 describes a method for introducing free amino or carboxyl groups onto a silica matrix; the groups may subsequently be covalently linked to a protein in the presence of a carbodiimide. Also, U.S. Patent No. 4,762,881 describes a method for attaching a polypeptide chain to a solid substrate by incorporating a light-sensitive unnatural amino acid group into the polypeptide chain and exposing the product to low-energy ultraviolet light.
A variety of techniques have also been developed for attaching oligonucleotides to surfaces. For example, U.S. Patent No. 4,542,102 describes a method employing a photochemically active reagent (e.g., a psoralen compound) and a coupling agent, which attaches the photoreagent to the substrate. Photoactivation of the photoreagent binds a nucleic acid sequence to the substrate to five a sur ace-bound probe for a complementary oligonucleotide. However, this method has low quantum yields in protic solvents, lacks spatial directability, and relies upon initial affinity between the photoreagent and nucleic acids to bind the nucleic acids to the surface prior to photoactivation.
U.S. Patent No. 4,937,188 describes methods for forming maleimide-thiol linkages between a solid support and a molecular tether* In one example, thiol groups on sepharose are reacted with malei ide groups on an RNA polymer, which serves as the tether, and the RNA polymer is reacted with a protein, also via a maleimide-thiol linkage. In another example, maleimide groups immobilized on a solid support are reacted with sulfhydryl RNAse forming RNAse-agarose. U.S. Patent No. 5,011,770 describes the use of a maleimide-thiol linkage to bind an -enzyme label to a binding protein, which in turn binds to single stranded DNA. The patent describes that the binding protein can also be attached to a solid support. The maleimide-thiol linkage is thus spatially separated from the actual linkage between the peptide and the solid support. PCT patent publication No. 90/07582 describes polyacrylamide supports on which are immobilized oligonucleotides. The oligonucleotides are derivatized at the 5'-terminus with thiol groups that are reacted with bromoacetyl groups on the polyacrylamide support during the immobilization process. PCT patent publication No. 91/00868 discloses solid supports on which oligonucleotides are immobilized via a 5'- dithio linkage. The immobilization of biological polymers on solid supports has also had significant impact on drug discovery and medical diagnostic methods. One important invention in these fields is described in U.S. Patent No. 5,143,854, and the continuations-in-part of that application, Serial No. 624,120, filed December 6, 1990, and Serial No. 805,727, filed December 6, 1991, and in PCT patent publication Nos. 90/15070 to Pirrung et al. and 92/10092 to Fodor et al. , each of which is incorporated herein by reference. In brief, these publications describe methods and reagents for synthesizing very large numbers of different compounds, particularly biological polymers, in distinct and spatially-addressable locations in a very small area on a substrate. Another description of the method is found in Fodor et al. , 15 Feb. 1991, Science 251:767-773- and the integration of the method with other drug discovery methods is described in Dower and Fodor, 1991, Ann. Rep. Med. Chem. ,26:271-280. A related method uses a photoactivateable derivative of biotin as the agent for immobilizing a biological polymer of interest onto a solid support; see PCT patent publication No. 91/07087 to Barrett et al. , incorporated herein by reference.
Recent approaches to genetic analysis are increasingly placing importance on performing parallel hybridizations in an array format. Applications of the parallel hybridization format include generating diagnostic arrays for tissue typing or diagnosis of genetic disorders
(see PCT patent publication No. 89/11548, incorporated herein by reference) , DNA sequencing by hybridization, DNA fingerprinting, and genetic mapping (see PCT patent publication Nos. 92/10587 and 92/10588, each of which is incorporated herein by reference; see also Khrapko et al. , 1991, J. DNA,, Seq. Map. .1:375-388). In these applications of probe arrays, the information content of the array increases as the number of probes is increased. The size limit of the array is dictated by the ability to automate and miniaturize the fabrication of the array.
Thus, there exists a need for improved methods for attaching a broad range of anti-ligands to predefined regions of a solid support surface. The methods should efficiently provide stable attachment of selected polymers to the activated surface regions, yet attachment should be restricted to the activated regions. The present invention fulfills these and other needs.
SUMMARY OF THE INVENTION Novel methods and compositions of matter are provided for synthesizing and immobilizing oligonucleotides and other biological polymers on predefined regions of a surface of a soiid support. The methods involve attaching to the surface a thiol functional group protected with a photochemical protecting group so that the thiol has very low reactivity for other functional groups reactive with thiols. The protected thiol is convertible by irradiation .o a fully reactive thiol capable of immobilizing a desired biological polymer such as a nucleic acid, protein, polysaccharide, or a monomer building block for such polymers. Predefined regions of the surface are selectively irradiated to convert the protected thiols in the predefined regions to reactive thiol groups. The desired biological polymers (or monomer) subsequently can be immobilized on the activated regions of the surface.
The spatial- addressability afforded by the method of the present invention allows the formation of patterned surfaces having preselected reactivities. For example, by using lithographic techniques known in the semiconductor industry, light can be directed to relatively small and precisely known locations on the surface. Thus, the present invention can be used to activate discrete, predetermined locations on the surface for attachment of biological polymers. The resulting surface will have a variety of uses. For example, direct binding assays can be performed in which nucleic acids in a sample can be simultaneously tested for affinity to a number of different oligonucleotide probes attached to the surface. Binding can be detected by a technique such as autoradiography when one of the binding moieties is radioactively labelled. Alternatively, fluorescence and optical measuring techniques can be used to detect the binding. By determining the locations and amount of label on the surface, one can simultaneously screen ligands for affinity to a plurality of anti-ligands.
Thus, the present invention provides methods for building arrays of biomolecules using photolithographic techniques. The method obviates the need to separate reactants spatially, because the substrate is unreactive until specific sites are activated with light. In one embodiment, the method involves the light-directed immobilization of oligonucleotides on a glass surface derivatized with a caged thiol reagent. The method can be used to fabricate large arrays of oligonucleotide probes.
A further understanding of the nature and advantages of the invention may be realized by reference to the remaining portions of the specification.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide; the results show that oligonucleotides activated with succinimidyl 6- maleimidylhexanoate are preferred for coupling to the thiol group-containing solid supports of the present invention (see Example 3) . FIG. 2 presents the results of fluorescence excitation scanning of a slide on which oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide in the presence of different additives; the results show that the anionic, zwitterionic, and neutral detergents do not appear to enhance coupling efficiency; the salts TMAC (trimethylammonium chloride) and LiCl give a moderate enhancement in coupling efficiency; and the cationic detergent DTAB causes a large enhancement in coupling efficiency at relatively low concentrations (see Example 4) .
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following terms have the following meanings and abbreviations as used herein:
"Surface" is any generally two-dimensional structure on a solid substrate and may have steps, ridges, kinks, terraces, and the like without ceasing to be a surface.
"Predefined Region" is a localized area on a surface which is or is intended to be activated. The predefined region may have any convenient shape, e.g. , circular, rectangular, elliptical, etc. "Crosslinking Group" is a bifunctional chemical entity that serves to connect a binding member to a surface. Usually, crosslinking groups are heterobifunctional and so have different chemical reactivities on either end of the linking group. "Biological Polymer" is a compound composed of monomeric units linked to one another that has biological activity or is reactive with a compound that has biological activity. Nucleic acids such as RNA and DNA are biological polymers, and peptides, proteins, and carbohydrates are also biological polymers. Synthetic, non-naturally occurring monomers can be used to construct a biological polymer. For instance, carbamates, phosphonates, sulfonamides, and sulfoxides are examples of monomers that can be used to construct biological polymers. "Anti-ligand" is a molecule or a complex of molecules that has an affinity for a given ligand and can be immobilized on a predefined region of a surface. Anti-ligands may be naturally-occurring or synthetic molecules. Anti-ligands can be employed in an unaltered state or as aggregates with other species. Anti-ligands can be reversibly attached, covalently or noncovalently, to a. binding member, either directly or via a specific binding substance. "Reversibly attached" means that the binding of the anti-ligand (or specific binding member or ligand) is reversible and has, therefore, a substantially non¬ zero reverse, or unbinding, rate. Such reversible attachments can arise from noncovalent interactions, such as electrostatic forces, van der Waals forces, hydrophobic (i.e., entropic) forces-, and the like. Furthermore, reversible attachments also may arise from certain, but not all, covalent bonding reactions. Examples include, but are not limited to, attachment by the formation of hemiacetals, hemiketals, imines, acetals, ketals, and the like (See, Morrison et al. , "Organic Chemistry" , 2nd ed. , Ch. 19 (1966), which is incorporated herein by reference) . Examples of anti-ligands that can be employed in the practice of the present invention include, but are not restricted to, receptors, such as cell membrane (such as those of B-cells, T-cells, and macrophages) receptors, polyclonal and monoclonal antibodi-es, and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials) , hormones, drugs, oligonucleotides, peptides, enzymes, lectins, sugars, oligosaccharides, cells, cellular membranes, cellular membrane transport proteins, and organelles.
"Ligand" is a solvated molecule that is recognized by a particular anti-ligand. Examples of ligands that can be investigated with the present invention include, but are not restricted to, agonists and antagonists for cell membrane receptors, toxins and venoms, antigenic determinants, such as viral epitopes, hormones, opiates, steroids, peptides, enzyme substrates, cofactors, drugs, lectins, sugars, oligonucleotides, oligosaccharides, and proteins.
The present invention provides methods for forming predefined regions on a surface of a solid support, wherein the predefined regions comprise caged thiol groups that can be activated and then used to immobilize ligands and/or anti- ligands. The caged thiols attached to the surface can be selectively activated in predefined regions via covalent linkages. The activated thiols are then used to immobilize compounds, e.g., anti-ligands, on the predefined regions of the surface. The above procedure can be repeated at the same or different sites on the surface so as to provide a surface with a plurality of regions containing the same or different ligands or anti-ligands. When the anti-ligands have a particular affinity for one or more ligands, screenings and assays for the ligands can be conducted in the regions of the surface containing the anti-ligands.
The present method employs novel caged thiols attached to the substrate. Caged (unactivated) thiols have relatively low reactivity with functional groups typically reactive with thiols when compared with uncaged thiols. Thus, the caged thiols are protected until a suitable source of energy is applied to the regions of the surface to be activated. Upon application of a suitable energy source, the caging groups labilize, thereby presenting the thiol. Typically, the energy source will -be light. Once the thiols on the surface are activated, the thiols can be attached to and reacted with a biological polymer of interest, typically a nucleic acid or other anti-ligand.
Prior to activation, however, the thiol groups on the surface are "caged" with a protecting group. The protecting groups can either be attached to the compounds carrying the thiol functional group after those compounds have been attached to the surface or, more preferably, the protecting groups will be attached to the compounds carrying the thiol functional group prior to attaching the thiol functional group to the surface. Surface attachment of compounds carrying a thiol group or protected thiol group can be effected through the use of crosslinking groups. The crosslinking groups will usually, though not always, be- heterobifunctional chemical species having- a first reactivity that permits the crosslinking group to bind readily to the surface and a second reactivity that permits the crosslinking group to -bind- readily with compounds carrying a thiol group or protected thiol group.
As noted above, predefined regions on the surface can be activated for ultimate immobilization of anti-ligands in the predefined regions by selectively irradiating predefined regions to convert photoactivatable thiol groups in the predefined region to fully reactive thiol groups. The free protecting group may or may not undergo decomposition reactions. The byproducts of irradiation of the protecting group will usually be washed from the surface if the byproducts interfere with subsequent reactions.
An immobilized anti-ligand on a surface will have a specific binding affinity for a particular ligand. If a surface comprising immobilized anti-ligands is exposed to a labeled ligand under conditions conducive to ligand binding to anti-ligand, then the resulting surface can be washed free of unbound ligand and analyzed for the presence of labeled ligand. The labels will provide markers localized at the predefined regions on the surface corresponding to the presence of anti- ligands for the ligand at those predefined regions. The presence of target ligand can be determined by analyzing appropriately for the loss or buildup of label on the predefined regions of the surface.
To prepare the surface comprising immobilized biological polymers of the invention, one first selects a substrate for surface modification. Virtually any solid substrate can be employed in the method of the invention. The substrate can be biological, nonbiological, organic, inorganic, or a combination of any of these materials, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, -pads, slices, films, plates, slides, etc. The substrate can have any convenient shape, such as a disc, square, sphere, circle, etc. The substrate and the surface of the substrate preferably form a rigid support on which to carry out the reactions described herein.
The substrate and the surface should also be chosen to provide appropriate light-absorbing characteristics. For instance, the substrate can be a polymerized Langmuir Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, Si02, SiN4, modified silicon, or any one of a wide variety of polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, or combinations thereof. Other substrate materials will be readily apparent to those of skill in the art upon review of this disclosure. In a preferred embodiment the substrate is flat glass or single-crystal silicon with surface features of less than 10 angstroms. Surfaces on the solid substrate will usually, though not always, be composed of the same material as the substrate. Thus, the surface may be composed of any of a wide variety of materials, for example, polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, membranes, etc., provided only that caged thiols can be attached to the surface of the substrate. Preferably, the surface will contain reactive groups, which could be carboxyl, amino, hydroxyl, or the like. Most preferably, the surface will be optically transparent and will have surface Si-OH functionalities, such as are found on silica surfaces.
The surface of the substrate is preferably provided with a layer of crosslinking groups, although one of ordinary skill will understand that the crosslinking groups are not required elements of the invention. The crosslinking groups are preferably of sufficient length to permit thiol groups on the surface, as well as biological polymers covalently attached to the thiol groups, to interact freely with compounds in solution. Crosslinking groups can be selected from any suitable class of compounds, for example, aryl acetylenes, ethylene glycol oligomers containing two to ten monomer units, dia ines, diacids, amino acids, or combinations thereof. Other crosslinking groups may be used in view of this disclosure. Crosslinking groups can be attached to the surface by a variety of methods that are readily apparent to one having skill in the art. For example, crosslinking groups may be attached to the surface by siloxane bonds formed via reactions of crosslinking groups bearing trichlorosilyl or trisalkoxy groups with hydroxyl groups on the surface of the substrate.
Preferably, the crosslinking group used with a glass surface is t-BOC-aminopropyltriethoxysilane. The crosslinking groups can optionally be attached in an ordered array, i.e., as parts of the head groups in a polymerized Langmuir Blodgett film. Clearly, the type of crosslinking group selected, and the method selected for attaching the crosslinking group to the surface, will depend primarily on the crosslinking group having suitable reactivity with the compound carrying the thiol group desired to be attached to the surface.
Additional length may be added to the crosslinking groups by the addition of single or multiple linking groups. Such linking groups are preferably heterobifunctional, having one end adapted to react with the crosslinking groups and the other end adapted to react with the compound carrying the thiol group or another linking group. The linking groups may be attached by a variety of methods that are readily apparent to one skilled in the art, for instance, by esterification or amidation reactions of an activated ester of the linking group with a reactive hydroxyl or amine on the free end of the crosslinking group. A preferred linking group is N-BOC-6- aminocaproic acid (or N-BOC-6-aminohexanoic acid) attached by the BOP-activated ester. After deprotection to liberate the free amine terminus, another N-BOC-aminocaproic linker can be added. Attachment of crosslinking and linking groups to caged thiol compounds are discussed more fully below.
Many methods are available for immobilizing the compound carrying the thiol group of the present invention on surfaces. The compound carrying the thiol group can be linked to the surface and later provided with protecting (caging) groups. More preferably, compounds carrying the thiol group will be attached to the surface in a protected form. The method chosen for linking the compound carrying the thiol group to the surface will depend upon the chemical properties of the compound carrying the thiol group selected for attachment to the surface. A preferred method for immobilizing the compound carrying the thiol group of the present invention involves chemical derivatization or activation of the caged compound carrying the thiol group prior to attachment to the surface or linker.
This derivative or activated species is then reacted with functionalities on the substrate to give the desired linkage. For example, one method for attaching a compound carrying the thiol -group to a surface employs a bifunctional crosslinking reagent, such as diepoxide, which both activates the surface and provides a group that reacts with an activated compound carrying the thiol group. Alternatively, some surfaces can be activated with cyanogen bromide. Likewise, in the presence of a carbodiimide or other activating agent, for example, an amine group on the surface can be coupled to a carboxyl group of a compound carrying the thiol group to effect the immobilization.
In one embodiment, the compound carrying the thiol group is a caged cysteine, or other thiol-containing synthetic or natural amino acid. Such compounds are useful in a wide variety of applications; for instance, one could carry out amino acid addition on either the amino or carboxyl groups of the protected cysteine and then, after photoactivation, derivatize the side chain of the cysteine residue. Such techniques will often employ different classes of protecting groups, so that one can modify the immobilized molecules at different reactive groups. These techniques include cyclization, where the cyclization step is controlled by the use of protecting groups on the two amino acid residues undergoing cyclization that are different from the protecting groups on amino acid residues that are not to be cyclized. See U.S. patent application Serial Nos. 796,727, filed November 22, 1991, and 946,239, filed September 16, 1992, each of which is incorporated herein by reference.
Many different protecting (caging) groups can be employed for modifying thiol groups to give the caged thiols of the present invention. The protecting groups should be sterically large enough to reduce the reactivity of the caged thiol with other substances to permit operability of the invention, although protecting groups utilizing other types of interactions, such as electronic, hydrophobic, etc., could be used. The selection of suitable caging groups will depend upon the size and chemical nature of the compound carrying the thiol group chosen and will- be readily apparent to one skilled in the art. The caging groups are photoactivatable. The properties and uses of photoreactive caged compounds have been reviewed. See McCray et al. , 1989, Ann. Rev. Biophvs. Biophys. Chem. .18.:239-270, which is incorporated herein by reference. Preferably, the photosensitive cages will be activatable by low energy ultraviolet or visible light. Many, although not all, of the photosensitive protecting groups are aromatic compounds. Suitable photoremovable protecting groups are also described in, for example, Patchornik, 1970, J. Am- Chem. Soc. 92:6333. and Amit et al. , 1974, J. Orq. Chem. 3_9_:192, which are incorporated herein by reference. See also, Calbiochem Catalog (San Diego, CA, 1989), pp. 244-247, incorporated herein by reference. More preferably, the photosensitive protecting group will be a nitro benzylic compound, such as o-nitrobenzyl or benzylsulfonyl groups. In a preferred embodiment, 6- nitroveratryloxycarbonyl (NVOC) ; 6-nitropiperonyloxycarbonyl (NPOC) ; alpha, alpha-dimethyldimethoxybenzyloxycarbonyl (DDZ) , methyl 6-nitroveratryloxycarbonyl (MenVOC) , methyl-6- nitropiperonyloxycarbonyl (MeNPOC) , or 1-pyrenylmethyl is employed.
Clearly, many photosensitive protecting groups are suitable for use in the present method. Some examples of acceptable photosensitive protecting groups are presented in Table l, below, together with their corresponding wavelengths for deprotection.
Table 1 Protecting Groups Group Deprotection Wavelength
6-nitroveratryloxycarbonyl (NVOC) UV (300-350 nm) dimethyldimethoxybenzyloxycarbonyl (DDZ) UV (280-300 nm) nitrobenzyloxycarbonyl (NBOC) UV (300-350 nm)
5-bromo-7-nitroindolinyl (BNI) UV (420 nm) O-hydroxy-alpha-methyl-cinnamoyl (HMC) UV (300-350 nm)
2-oxymethylene anthraquinone (OMA) UV (350 nm)
Once the surface is covered with a plurality of caged thiol groups, selected regions of the surface may be irradiated to provide free thiols on the surface. In a preferred embodiment, the radiation is UV, near IR, or visible light. The light source may be coherent or noncoherent. In some embodiments, the exposed area is less than about 1 cm2 or less than about 1 mm2. In preferred embodiments the irradiated area will be composed of a pattern of smaller, discrete irradiated areas, each of which is less than about 10,000 μm2 or, more preferably, less than about 100 μm2. Preferably, each individual synthesis site in the pattern is about 50 to 500
/--M2. Spaces between activated regions are not optional and, if used, will generally be greater than about 1 μm. Exposure of the surface to light will typically be carried out with a suitable mask using photolithographic techniques well known in the semiconductor industry and described in, for example, Sze, VLSI Technology. McGraw-Hill (1983) , which is incorporated herein by reference. See U.S. Patent No. 5,143,854.
In one embodiment, the mask is a transparent support material coated with a layer of opaque material (i.e., chrome- plated glass) . Portions of the opaque material are removed (or never deposited) , leaving a pattern that matches the precise pattern desired on the substrate surface. Alternatively the mask can be a sheet or film composed of a non-transparent substance (i.e., anodized aluminum) ,- which sheet or film has been perforated in the desired pattern. The mask is brought into close proximity with or directly into contact with the surface. Openings -in the mask correspond to locations on the surface where one desires to photoremove protecting groups from thiol groups. Alignment may be performed using conventional alignment techniques in which alignment marks are used to overlay accurately successive masks with previous patterning steps. Other alignment techniques may be used, for example, interferometric techniques such as the one described in Flanders et al. , 1977, App. Phys. Lett. 3_l:426-428, which is incorporated herein by reference.
To enhance contrast of light applied to the substrate, one may place contrast enhancement materials between the mask and the substrate. This contrast enhancement layer may comprise a molecule, such as -quinone diazide, which is decomposed by light. The light may be from a conventional incandescent source, an arc lamp, a laser, or the like. If noncoherent sources of light are used, one may utilize a thick or multi-layered mask to prevent spreading of the light on the substrate. Generally, lasers may be preferable, because lasers can more easily provide wavelengths particularly suited for a chromophore of the photosensitive group.
While the invention is illustrated primarily herein by way of the use of a light source and mask to illuminate the substrate, other techniques may also be used. For example, the substrate may be rotated or oriented under a modulated laser or diode light source. Such techniques are discussed in, for example, U.S. Patent No. 4,719,615, which is incorporated herein by reference. The substrate may be irradiated either in contact with or not in contact with a solution but usually is irradiated in contact with a solution.
The solution may contain reagents to prevent byproducts of irradiation from interfering with subsequent binding reactions. Such byproducts might include, for example, carbon dioxide, nitrosocarbonyl compounds, styrene derivatives, indole derivatives, and products of the photochemical reactions of such compounds. Reagents added to the solution may include, for example, acidic or basic buffers, thiols, substituted hydrazines and hydroxylamines, reducing agents (e.g., NADH,
DTT, or bisulfite ion) , or reagents known to react with a given functional group (e.g., aryl nitroso plus glyoxylic acid aryl form hydroxamate plus C02) . Preferably, however, protecting groups will be selected that do not cause significant interference with the binding reactions. Also, wash steps can be incorporated so that the byproducts do not interfere with the reactions.
Once localization of the anti-ligand is complete, the light pattern can be changed and the same or a different anti- ligand, ligand, polymer, or monomer can be localized at other discrete sites on the- surface. Anti-ligands that are nucleic acids are especially preferred. In a preferred embodiment, a plurality of nucleic acid anti-ligands are immobilized on a surface by first attaching photoreactive caged thiols to the surface. The caged thiols on a predefined region of the surface are exposed to light to give reactive thiol groups. The reactive thiol groups on the predefined region are then incubated with a first activated nucleic acid anti-ligand to be immobilized, the surface is washed free of unreacted nucleic acid, and the surface is incubated with a desired ligand. The exact incubation conditions, e.g., time, temperature, pH, etc., will depend upon the species used and will be readily apparent to one skilled in the art. After washing the surface free of unbound nucleic acid, the above steps can be repeated on a different region of the surface with a different nucleic acid. In this fashion, a small, dense array of-, e.g., oligonucleotide probes, can be prepared. A surface prepared according to the methods described above can be used to screen for ligands having high affinity for immobilized anti-ligands. Screening can be performed by immobilizing a plurality of anti-ligands on predefined regions of a surface by the methods described above. A solution containing a marked (labelled) ligand is introduced'to the surface and incubated for a suitable period of time. The surface is then washed free of unbound ligand, and the anti- ligands having high affinity for the ligand are identified by identifying those regions on the surface where markers are located. Suitable markers include, but are not limited to, radiolabels, chromophores, fluorophores, chemiluminescent moieties, and transition metals. When autoradiography is the detection method used, the marker is a radioactive label, such as 32P. The marker on the surface is exposed to X-ray film, which is developed and read out on a scanner. An exposure time in the range of 1 to 24 hours is typical. Fluorescence detection using a fluorophore label, such as fluorescein, attached to the ligand will usually require much shorter exposure times. Alternatively, the presence of ligands may be detected using a variety of other techniques, such as an assay with a labelled enzyme, antibody, or the like. Other techniques using various marker systems for detecting bound ligand will be readily apparent to those skilled in the art. See U.S. Patent No. 5,143,854. In a preferred embodiment, a substrate prepared as discussed above can be exposed to a solution containing one or more ligands such as nucleic acids. The ligand can be labeled in any of a variety of ways, but in one embodiment, the ligand is an oligonucleotide probe having a radioactive (or other) label. The ligand nucleic acid binds (hybridizes) with high affinity to an immobilized nucleic acid previously localized on the surface and to the complementary labeled probe. Hybridization conditions are known in the art, but the arrays of the invention allow one to use very small volumes of target- containing solution for analysis. In fact, by using micropipettes to deliver very small volumes (i.e., 1 to 5 μL or less) very precisely, one can allow evaporation to drive hybridization. After washing the surface free of nonspecifically bound ligand and labeled probe, the surface is placed proximate to X-ray film, if a radioactive label is employed, to identify the nucleic acids on the surface complementary to the nucleic acid ligand. Alternatively, a fluorescent label can be used, and detection can be accomplished with a charge-coupled device (CCD) , fluorescence microscopy, or laser scanning. A related labeling technique involves the use of a labeled probe in solution that will hybridize with the target nucleic acid ligand without interferring with hybridization of the ligand to the immobilized probe.
In another embodiment useful for performing many parallel hybridization reactions in solution in a single reaction vessel using an immobilized array of probes, one uses a set of capture probes in solution. The capture probes are designed to have a sequence complementary to the target sequence to be detected and a sequence complementary to an immobilized probe located at one or more discrete locations on the surface of the substrate. In this system, either the capture probe is labeled or another labeled probe complementary to the target sequence to be detected is employed. This system allows the hybridization of probe to target sequence to be carried out in solution, because the immobilized probe array does not have to be (but can be, if desired) present in the reaction mixture during hybridization of the capture probe to the target sequence. This system also allows one to design the capture sequence, the complementary sequence of nucleotides in the immobilized probe and the capture probe, without constraint from the target sequence. These advantages allow one to perform an assay for many different target nucleic acids simultaneously and yet still identify whether any particular target nucleic acid is present in the sample tested. Quantitative assays for ligand concentrations can also be performed according to the present invention. In a direct assay method, the surface containing localized anti- ligands prepared as described above is incubated with a solution containing a labeled ligand for a suitable period of time. The surface is then washed free of unbound ligand. The amount of label present at predefined regions of the surface is then measured and can be related to the amount of ligand in solution. Methods and conditions for performing such assays are well-known and are presented in, for example, Hood et al., Immunology (Benjamin/Cummings 1978) and Harlow et al..
Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory 1988) , each of which is incorporated herein by reference. See also U.S. Patent No. 4,376,110, incorporated herein by reference, for methods of performing sandwich assays. The precise conditions for performing these steps will be apparent to one skilled in the art.
A competitive assay method can also be employed using the methods and reagents of the present invention. Such a method involves immobilizing anti-ligands on predefined regions of a surface as described above. An unmarked ligand is then bound to anti-ligands on the surface having specific binding affinity for the ligand. A solution containing marked ligand is then introduced to the surface and incubated for a suitable time. The surface is then washed free of unbound reagents, and the amount of marker remaining on the surface is measured.
Alternatively, marked and unmarked ligand can be exposed to the surface simultaneously. The amount of marker remaining on predefined regions of the surface can be related to the amount of unknown ligand in solution. The invention is illustrated in the Examples below primarily with reference to the identification of specific nucleic acid sequences in a sample. The invention will, however, find many other uses. For example, the invention can be used in information storage (e.g., on optical disks), production of molecular electronic devices, production of stationary phases in separation sciences, and in immobilization of- cells, proteins, lectins, nucleic acids, polysaccharides and the like in any desired pattern on a surface via molecular recognition of a specific anti-ligand linked via a thiol group to a surface of a substrate.
The above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined not with reference to the above description or the following Examples, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
Example 1 Preparation of Substrate and Thiol-derivatized Surface A. Preparation of Substrate Surface Commercially available glass microscope slides (for example, 1" x 3" smooth cut, 0.7 mm thick, anti-scratch coated slides or 2" x 3" smooth cut, 0.7 -mm thick, anti-scratch coated slides from Erie Scientific) were derivatized with t-BOC- aminopropyltriethoxy silane in substantial accordance with the procedure described in J. Chromatography 97:33 (1974), incorporated herein by reference.
Thus, the slides were cleaned by soaking in 10% Micro detergent (Baxter) , individually scrubbed, and immersed in deionized water. The slides were then subjected to a 10 minute sonication in a 70°C solution of 10% Micro detergent and rinsed ten times with deionized water. This process was followed by a three minute immersion in a 70°C solution of 10% (w/v) NaOH. The slides were then rinsed ten times with deionized water, and then immersed for one minute in 1% HC1. The slides were then again rinsed ten times with deionized water, and then subjected to another 10 minute sonication in 70°C deionized water, after which the slides were rinsed three to four times in deionized water. The slides were then ethanol rinsed and dried with nitrogen or argon. The slides were then inspected visually for spots and scratches in a yellow light with a black background, and any slides that were scratched- or spotted or that still retained the anti-scratch coating were either discarded or recleaned.
An alternate or additional cleaning procedure is carried out as follows. The slides are loaded into teflon racks and subjected to a thirty minute immersion in a solution composed of Nochromix (Aldrich) with 36 g/L of concentrated sulfuric acid (which can be regenerated if discolored) that has been filtered (glass fiber filter) to remove particulate matter. Occasional agitation is provided during the thirty minute immersion step. The slides are then rinsed for one minute in deionized water with vigorous agitation. The slides are then placed for ten minutes in a rinse tank with 14 psi argon or nitrogen bubbling, a full open deionized water tap, and occasional agitation.
The slides are then immersed for three minutes in a 70°C solution of 10% (w/v) NaOH, followed by a one minute rinse with deionized water and vigorous agitation, followed by a ten minute rinse in a rinse tank. The slides are then immersed for one minute in 1% HC1 and then rinsed for five minutes in a rinse tank. The slides are then ethanol rinsed, dried with nitrogen or argon, and inspected visually for spots and scratches.
The t-BOC aminopropyl derivatization is carried out as follows. The slides are loaded into plastic staining jars, with about nine slides per jar. Preferably, the slides are completely dry when placed in the staining jars, and the silation reagents are added as follows. The silation reagent is a premixed solution of a 1:10 molar ratio of t-BOC- aminopropyltriethoxysilane:methyltriethoxysilane (i.e., 1 L of t-BOC-aminopropyltriethoxysilane and 5.86 mL of methyltriethoxysilane, which is kept anhydrous and stored under argon) . The silation reagent is diluted to 1% (v/v) in dichloromethane (DCM) , mixed well, and 60 mL of the diluted silation reagent are added to each jar. The jars are capped and incubated overnight at room temperature. Then, the slides are removed from the jar, rinsed first with DCM and then with toluene and then dried immediately with argon. The slides are then loaded onto glass drying racks, inspected for streaks, and allowed to stand for approximately thirty minutes. The slides are then baked for one hour in a 100°C oven with the glass racks in metal trays covered with foil. The oven should be no hotter than 110°C. The slides are then cooled and optionally numbered with an engraving tool.
The slides, prepared as described above, were then incubated at room temperature in a solution of 50% trifluoroacetic acid/50% DCM for forty minutes to remove the t- BOC protecting group. After being washed sequentially with DCM and then twice with a solution of 5% diisopropylethylamine (DIEA) in methylene chloride for 5- minutes each wash, the slides were then washed with methylene chloride, then with ethanol, and then the slides were dried with argon. The slides were derivatized within one hour of drying.
B. Preparation of Nitroveratrylthiolpropionic Acid Nitroveratrylthiolpropionic acid was prepared in substantial accordance with the protocols set forth in Patchornik et al.. , 21 Oct. 1970, J. Am« Chem. Soc. 92(21) :6333- 6335, incorporated herein by reference.
About 500 mg (0.0018 moles) of bromonitroveratryl (NVBr) were added to a solution containing 160 μL (0.0018 moles) of thiolpropionic acid (HSCH2CH2C02H) , 6 mL of dimethylformamide (DMF) , and 364 mg (0.0036 moles) of triethylamine (Et3N) . After about five minutes, a precipitate -(Et3N+HBr) formed, and the reaction was deemed complete after analysis with thin layer chromatography (TLC in 10% methanol/dichloromethane) . The reaction mixture was then diluted with 100 mL of methylene chloride and washed with 50 mL of 1 N- NaOH. The aqueous phase was separated, acidified with 1 N HC1, extracted with methylene chloride, and then the organic layer was dried (Na2S04) , and ihen rotary evaporated to dryness. About 0.54 g of nitroveratrylthiolpropionic acid was obtained. The product can be further purified by dissolving the product in ethanol, adding five volumes of water, and collecting the needle-shaped crystals by filtration.
C. Coupling of Nitroveratrylthiolpropionic Acid to Substrate Surface
A solution composed of 60 mg of nitroveratrylthiolpropionic acid, 70 μL of DIEA, 29.8 mg of HOBT (1-hydroxybenzotriazole hydrate), and 0.2 mL of DMF was mixed at room temperature for 10 minutes with a solution composed of 88.5 mg of BOP (benzotriazol-1-yloxytris-
(dimethylamino) phosphonium hexafluorophosphate) and 0.2 L of DMF. The resulting mixture was then diluted with 1.6 mL of DMF,- and about 0.5 mL of the resulting mixture was applied to each 1" x 3" slide. The slides were then immersed with a 3:1 (v/v) solution of pyridin :acetic anhydride with 0.1% DMAP (4- dimethylaminopyridine) . The resulting slides were then used in the coupling and hybridization experiments described below.
Example 2 Coupling of Fluorescein Maleimide to Substrate Surface A glass microscope slide- prepared as described in Example IC was mounted on a flow cell and illuminated through a 500 μm 500 μm checkerboard-pattern mask (Photo Sciences Inc. , Torrance, CA) using broad-band UV/blue light. This pattern was repeated in triplicate on each slide, and the illumination was carried out so that one region underwent a four minute photolysis, a second region underwent a two minute hydrolysis, and a third region underwent a one minute photolysis. The light source was a 500 W Mercury arc lamp (Oriel Model 87330) equipped with a 350 nm - 450 nm dichroic reflector that produced actinic light having an intensity of 12 mW/cm2 as measured through a 360 nm bandpass filter. The derivatized surface was photolyzed in flowing dioxane for 15 minutes and then rinsed in ethanol and dried with argon. About 4.3 mg of fluorescein maleimide (Molecular
Probe) were dissolved in 10 mL of warm DMF to obtain a one mM solution of fluorescein maleimide. This solution was allowed to cool to room temperature, and then the slide was immersed in the solution and incubated at room temperature for two hours with gentle agitation. The slide was then removed from the solution and rinsed sequentially with DMF, ethanol, methylene chloride, and again with ethanol, and then the slide was dried with argon.
The slide was examined with a scanning fluorescence microscope (Zeiss Axioskop equipped with a Newport Model PM500- C motion controller, a Spectra-Physics Model 2020 argon-ion laser producing a 488 nm excitation light; and a 520 nm long- pass emission filter) interfaced with a photon-counting device (Hamamatsu Model 9403-02 photomultiplier; Stanford Research Systems Model SR445 amplifier and Model SR430 multichannel sealer, IBM compatible PC) to generate a two-dimensional image consisting of fluorescence intensity data as a function of x,y position. The results of this analysis revealed the pattern of illuminated and dark squares expected from the fluorescein maleimide coupling to the deprotected thiol groups in the illuminated squares. This experiment demonstrates that the photochemically protected thiols are competent for coupling to a maleimide-containing compound after photodeprotection.
Example 3 Coupling of Oligonucleotides with Thiol-reactive Groups to Substrate Surface This example shows the results of a test for the effectiveness of several different thiol-reactive groups that, when attached to an oligonucleotide, enable covalent coupling to thiol-derivatized glass slides.
A 5*-fluoresceinated 3'-C6-amino oligonucleotide probe (designated CAP2, which was prepared using the Clonetech reagent 3*-C6-amino-modifier-CPG) was activated with the following heterobifunctional reagents: (1) succinimidyl bromoacetate (BrAc-NHS) ; (2) succinimidyl iodoacetate (IAc- NHS) ; (3) succinimidyl 6-( (iodoacetyl)amino)hexanoate (SIAX) ; (4) succinimidyl 6-(6-(( (iodoacetyl)amino)hexanoyl)amino)- hexanoate (SIAXX) ; and (5) succinimidyl 6-maleimidylhexanoate (EMCS) . The activation reactions were carried out in separate reaction mixtures containing: 0.2 mM oligonucleotide; 0.25 M Na borate, pH = 8.3; 40 nK of one of the five NHS esters listed above; 24% acetonitrile; and 24% DMF, typically in a total volume of 200 μL. The reaction was incubated at 25°C for 30 minutes, and the resulting modified oligonucleotide was desalted on a G-25 spin column (unbuffered water) and then used without further purification at a concentration of about 100 μM (determined spectrophotometrically) . Polyacrylamide gel electrophoresis assays after quenching- with a fluorescent thiol indicated that about 75% of the oligonucleotides were modified in the.reaction.
The modified oligonucleotides were applied at a concentration of about 100 μM in unbuffered water to a freshly photolyzed thiol-containing slide prepared as described in Example 1. About 5 μL of each oligonucleotide were applied to each well on the slide. The wells were created on the slide using a twelve well template with O-rings to seal the template to the slide. After each oligonucleotide was added to a well, about 5 μL of a buffer solution composed of 100 mM HEPES, pH = 8.0, 5 mM EDTA, and 5 mM DTAB (dodecyl trimethyl ammonium bromide) were added to each well to initiate the reaction. The reaction mixtures were incubated at room temperature for four hours in the dark, and then the wells were rinsed with water and the slide was removed and washed in a solution composed of 2%- SDS in Tris-buffer at pH = 8 at 65°C overnight. The slides were then washed with water and ethanol, then dried. Surface fluorescence on the- slide was then imaged using a scanning 488 nm laser induced fluorescence microscope. Average fluorescence intensities per pixel in the immobilization sites were used as a measure of oligonucleotide binding (covalent coupling to surface thiols) .
The results of the scanning are presented graphically in Pig. 1. The results show that none of the haloacetyl activating groups enhanced binding significantly above the background non-specific binding but that the maleimide activating group (EMCS) enhanced binding five-fold over background non-specific binding. These results do not indicate that the other activating groups tested (including cyanuric chloride, tested in a separate experiment) are unsuitable for coupling to the substrates of the invention but instead indicate that of the activating groups tested, the maleimide activating group is preferred under the conditions employed.
Example 4
Coupling Efficiency of Maleimide-activated Oligonucleotides to Substrate Surface — Effect of Various Additives
This example shows the results of the addition of a variety of additives on the coupling efficiency of a maleimide- activated, 5'-fluoresceinated oligonucleotide to thiol- derivatized slides. In this example, the 5*-fluoresceinated 3'—C6-amino oligonucleotide was activated with succinimidyl 6- maleimidylhexanoate and applied to a freshly photolyzed slide as a solution in water in substantial accordance with the procedure set forth in Example 3.
Each different additive was added to the coupling initiation buffer (100 mM HEPES, pH = 8.0, 5 mM EDTA, and the additive) . After the coupling reaction, the slides were washed and scanned as described in Example 3. The results of the scanning are presented graphically in Fig. 2. The results show that the anionic, zwitterionic, and neutral detergents did not appear to enhance coupling efficiency; the salts TMAC (trimethylammonium chloride) and LiCl gave a moderate enhancement in coupling efficiency; and the cationic detergent DTAB caused a large enhancement in coupling efficiency at relatively low concentrations (2.5 mM; at higher concentrations, greater than 10 mM, the oligonucleotide precipitated) . Other additives of interest include compounds such as spermidine, spermine, polyamines, polyethyleneimine, and other cationic detergents similar to DTAB, and other salts similar to LiCl.
Example 5 Hybridization of Nucleic Acids to Immobilized Oligonucleotide Two glass slides prepared in accordance with the procedures set forth in Examples 3 and 4 were tested for ability to hybridize specifically with a complementary oligonucleotide. The two slides differed with respect to the additive present during the coupling reaction; one slide was coupled to oligonucleotide in the presence of LiCl, the other in the presence of DTAB.
The slides were prehybridized individually in heat sealed bags at 56°C with a solution composed of 6X SSC, 6X Denhardt's solution, 0.5% SDS, and 100 μg/mL of sheared, denatured, salmon sperm DNA. The hybridization reaction was carried out at 53.5°C (TM minus 5°C) in prehybridization buffer containing 1 pmole of a 32P-end labeled 60mer probe (specific activity of 1.5 x 108 CPM/μg) containing a 30 nucleotide segment perfectly complementary to the covalently coupled oligonucleotide probe. The hybridized slides were evaluated in a beta plate counter and by autoradiography.
The results showed that the labeled probe hybridized specifically to the covalently coupled oligonucleotide with very little background.
Example 6
Rehvbridization of Nucleic Acids to Oligonucleotide-derivatized Substrate Surface
The slides hybridized to labeled probe in accordance with the procedure of Example 5 were washed three times with a
100°C solution of 0.01% SDS. The slides were then allowed to expose XAR film overnight at -70°C to determine whether the labeled probe had been removed. The results showed complete removal of the probe from all but two sites, which showed only weak signal.
Rehybridization with the labeled probe of Example 5 was carried out using the Stratagene Qwik-Hyb™ hybridization accelerator solution following the package insert directions.
Other hybridization acceleration reagents that can be employed in the method of the present invention include Al protein, RecA protein, SSB, dextran sulfate, ficoll, phenol, and detergent.
Prehybridization was carried out for 15 minutes at 53.5°C, and then 100 μL of 10 mg/mL salmon sperm DNA was added to the slides together with 10 μL (one pmole) of the labeled probe.
The hybridization reaction was carried out at 53.5°C for one hour. The slides were washed and then allowed to expose XAR film overnight at -70°c.
The results showed that the slides to which oligonucleotide had been coupled in LiCl gave an even stronger signal than after the first hybridization and that the slides to which oligonucleotide had been coupled in DTAB gave a weaker but still clear signal than after the first hybridization. Both slides showed very little background signal.
Example 7
Specific Hybridization of Nucleic Acids to Immobilized Oligonucleotide Probe Array A slide prepared as described in Example 1 is photolyzed under dioxane and then rinsed with ethanol and dried under a nitrogen stream. The slide is clamped to a template that forms a well over the photolyzed area, and 20 μL of a 100 μM solution of 3•-EMCS-activated probe CAP2 (δ'-CCAACTCTTTTTCCGAAGGTAACTGGCTTC [SEQ. ID NO. 1]) in unbuffered water and HEPES/EDTA/DTAB buffer are added to the well. The slide and template are then incubated at room temperature for two hours, the reaction is quenched by the addition of N-ethyl maleimide, and the slide is rinsed liberally first with water and then with dioxane. The slide is then re-photolyzed to activate a different region on the slide and then coupled to 3'-ECMS-activated probe CAP5 (51-
GTTCCGCAGGTTCTCTCG- GTCAGTCTGTGC [SEQ. ID NO.2]). After the coupling reaction is quenched as before, the slide is rinsed with water and then washed for 12 hours in a 65°C solution of 2% SDS. The slide is then hybridized to a first labeled target nucleic acid complementary to probe CAP2, and the specificity of hybridization is determined. The slide is then washed to remove the labeled target nucleic acid, and a second labeled target nucleic acid complementary to probe CAP5 is added, and the specificity of hybridization is determined. The results demonstrate that the methods and reagents of the invention provide a very sensitive and specific assay for target nucleic acid sequences. SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: McGall, Glenn H.
Fodor, Stephen P. . Sheldon, Edward L.
(ii) TITLE OF INVENTION: Spatially-Addressable Immobilization of
Oligonucleotides and Other Biological Polymers on Surfaces
(iii) NUMBER OF SEQUENCES: 2
(ΪV) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: William M. Smith
(B) STREET: One Market Plaza, Steuart Tower, Suite 2000
(C) CITY: San Farancisco
(D) STATE: California
(E) COUNTRY: USA CF) ZIP: 94105
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE: 04/24/92
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Smith, William M.
(B) REGISTRATION NUMBER: 30,223
(C) REFERENCE/DOCKET NUMBER: 11509-41
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415-543-9600
(B) TELEFAX: 415-543-5043
(2) INFORMATION FOR SEQ ID NOM:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi> SEQUENCE DESCRIPTION: SEQ ID NO:l: CCAACTCTTT TTCCGAAGGT AACTGGCTTC 30
SUBSTITUTE SHEET 29
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GTTCCGCAGG TTCTCTCGGT CAGTCTGTGC
SUBSTITUTE SHEET

Claims

WHAT IS CLAIMED IS:
1. A method for forming predefined regions on a surface of a solid support, the -predefined regions capable of selectively immobilizing a biological polymer, the method comprising: a) attaching to the surface a compound carrying a thiol group, which thiol group is covalently coupled to a photochemically removable protecting group; and b) selectively irradiating the predefined regions of the surface to remove said photochemically removable protecting group from said thiol group in the predefined regions.
2. The method of claim 1, wherein said solid support is selected from the group consisting of polymerized Langmuir Blodgett film, functionalized glass. Si, Ge, GaAs, GaP, Si02, SiN4, modified silicon, (poly)tetrafluoroethylene, and (poly)vinylidenedifluoride solid supports.
3. The method of claim 1, wherein said photochemically removable protecting group is selected from the group consisting of 6-nitroveratryloxycarbonyl, dimethyldimethoxybenzyloxycarbonyl, nitrobenzyloxycarbonyl, 5-bromo-7-nitroindolinyl, O-hydroxy-alpha-methyl-cinnamoyl, methyl 6-nitroveratryloxycarbonyl, methyl-6- nitropiperonyloxycarbonyl, and 2-oxymethylene anthraquinone.
4. The method of claim 1, wherein said solid support is a functionalized glass slide and said photochemically removable protecting group is 6-ntroveratryloxycarbonyl.
5. The method of claim 4, wherein said functionalized glass slide has been functionalized by treatment with t-BOC- aminopropyltriethoxysilane.
6. The method of claim 4, wherein said compound carrying a thiol group is nitroveratrylthiolpropionate.
7. The method of claim 4, which method further comprises coupling an activated oligonucleotide to said thiol group in said predefined regions.
8. The method of claim 7, wherein said functionalized glass slide has been functionalized by treatment with N-BOC- aminopropyltriethoxysilane and said --:ompound carrying a thiol group is nitroveratrylthiolpropionate.
9. The method of claim 7, wherein said activated oligonucleotide has been activated with succinimidyl 6-maleimidylhexanoate.
10. The method of claim 8, wherein said coupling step is carried out in the presence of a cationic detergent.
11. The method of claim 10, wherein said cationic detergent is DTAB.
PCT/US1993/003767 1992-04-24 1993-04-21 Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces WO1993022680A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/874,849 1992-04-24
US07/874,849 US5412087A (en) 1992-04-24 1992-04-24 Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces

Publications (1)

Publication Number Publication Date
WO1993022680A1 true WO1993022680A1 (en) 1993-11-11

Family

ID=25364706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/003767 WO1993022680A1 (en) 1992-04-24 1993-04-21 Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces

Country Status (3)

Country Link
US (1) US5412087A (en)
AU (1) AU4110793A (en)
WO (1) WO1993022680A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021265A1 (en) * 1994-02-01 1995-08-10 Isis Innovation Limited Methods for discovering ligands
US5604097A (en) * 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
EP0764214A1 (en) * 1994-06-08 1997-03-26 Affymax Technologies N.V. Bioarray chip reaction apparatus and its manufacture
EP0804731A1 (en) * 1994-06-17 1997-11-05 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for fabricating microarrays of biological samples
US5695934A (en) * 1994-10-13 1997-12-09 Lynx Therapeutics, Inc. Massively parallel sequencing of sorted polynucleotides
US5858666A (en) * 1996-08-29 1999-01-12 Biotechnology Research And Development Corporation Apparatus and method of detection employing an AC frequency sensor array
EP0920440A2 (en) * 1996-02-09 1999-06-09 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
DE19853640A1 (en) * 1998-11-20 2000-06-08 Molecular Machines & Ind Gmbh Multi-vessel arrangement with improved sensitivity for optical analysis
US6138077A (en) * 1994-10-13 2000-10-24 Lynx Therapeutics, Inc. Method, apparatus and computer program product for determining a set of non-hybridizing oligonucleotides
WO2001001142A2 (en) * 1999-06-29 2001-01-04 Chiron Corporation Arrays of biopolymeric agents and method for their production and use
US6280935B1 (en) 1994-10-13 2001-08-28 Lynx Therapeutics, Inc. Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
EP1421201A2 (en) * 2001-07-31 2004-05-26 New York Institute Of Technology Methods for immobilizing molecules to a solid phase and uses thereof
DE10260431A1 (en) * 2002-12-21 2004-07-01 Forschungszentrum Jülich GmbH Self-justifying immobilization of living cells on a silicon substrate, useful in preparation of sensors, by attaching mutually interacting molecules to surfaces of cells and substrate
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7097980B2 (en) 1996-05-29 2006-08-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US7138268B2 (en) 1995-03-28 2006-11-21 Agilent Technologies, Inc. Dry biochemical assay plate and method for making the same
US7195872B2 (en) 2001-11-09 2007-03-27 3D Biosurfaces, Inc. High surface area substrates for microarrays and methods to make same
US7455965B2 (en) 2000-04-14 2008-11-25 Cornell Research Foundation, Inc. Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction
US7932213B2 (en) 1999-05-11 2011-04-26 President And Fellows Of Harvard College Small molecule printing
USRE43097E1 (en) 1994-10-13 2012-01-10 Illumina, Inc. Massively parallel signature sequencing by ligation of encoded adaptors
US8140148B2 (en) 1998-01-20 2012-03-20 Boston Scientific Scimed Ltd. Readable probe array for in vivo use

Families Citing this family (536)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6955915B2 (en) * 1989-06-07 2005-10-18 Affymetrix, Inc. Apparatus comprising polymers
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5547839A (en) * 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
DE69132843T2 (en) 1990-12-06 2002-09-12 Affymetrix Inc N D Ges D Staat Identification of nucleic acids in samples
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6589726B1 (en) 1991-09-04 2003-07-08 Metrigen, Inc. Method and apparatus for in situ synthesis on a solid support
US6921636B1 (en) * 1991-09-04 2005-07-26 Metrigen, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5849486A (en) * 1993-11-01 1998-12-15 Nanogen, Inc. Methods for hybridization analysis utilizing electrically controlled hybridization
US6051380A (en) * 1993-11-01 2000-04-18 Nanogen, Inc. Methods and procedures for molecular biological analysis and diagnostics
US5677195A (en) * 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US6943034B1 (en) * 1991-11-22 2005-09-13 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
EP1382386A3 (en) * 1992-02-19 2004-12-01 The Public Health Research Institute Of The City Of New York, Inc. Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids
JPH0622798A (en) * 1992-07-07 1994-02-01 Hitachi Ltd Method for determining base sequence
US6436635B1 (en) * 1992-11-06 2002-08-20 Boston University Solid phase sequencing of double-stranded nucleic acids
US5795714A (en) * 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
EP0687307A4 (en) * 1993-02-18 1997-11-26 Univ Massachusetts Medical Inhibition of tax-mediated increase in dna binding
US6156501A (en) * 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US7375198B2 (en) * 1993-10-26 2008-05-20 Affymetrix, Inc. Modified nucleic acid probes
US20030232361A1 (en) * 1993-10-26 2003-12-18 Affymetrix, Inc. Nucleic acid array preparation using purified phosphoramidites
US6045996A (en) * 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US7378236B1 (en) * 1994-06-17 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Method for analyzing gene expression patterns
US7323298B1 (en) 1994-06-17 2008-01-29 The Board Of Trustees Of The Leland Stanford Junior University Microarray for determining the relative abundances of polynuceotide sequences
US6327031B1 (en) * 1998-09-18 2001-12-04 Burstein Technologies, Inc. Apparatus and semi-reflective optical system for carrying out analysis of samples
US8236493B2 (en) * 1994-10-21 2012-08-07 Affymetrix, Inc. Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US5585069A (en) * 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
EP0791238B1 (en) * 1994-11-10 2004-09-22 Orchid BioSciences, Inc. Liquid distribution system
US5603351A (en) 1995-06-07 1997-02-18 David Sarnoff Research Center, Inc. Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device
US6475721B2 (en) * 1995-03-04 2002-11-05 Boston Probes, Inc. Sequence specific detection of nucleic acids using a solid carrier bound with nucleic acid analog probes
US7803529B1 (en) 1995-04-11 2010-09-28 Sequenom, Inc. Solid phase sequencing of biopolymers
US20060063193A1 (en) * 1995-04-11 2006-03-23 Dong-Jing Fu Solid phase sequencing of double-stranded nucleic acids
US5830539A (en) * 1995-11-17 1998-11-03 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for functionalizing and coating substrates and devices made according to the methods
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
US6953663B1 (en) 1995-11-29 2005-10-11 Affymetrix, Inc. Polymorphism detection
US20110028350A1 (en) * 1995-12-15 2011-02-03 Affymetrix, Inc. Photocleavable protecting groups
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6063633A (en) 1996-02-28 2000-05-16 The University Of Houston Catalyst testing process and apparatus
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
US6251691B1 (en) 1996-04-25 2001-06-26 Bioarray Solutions, Llc Light-controlled electrokinetic assembly of particles near surfaces
US5872015A (en) * 1996-05-10 1999-02-16 Board Of Trustees Of The University Of Illinois Molecular diversity screening method
US5958342A (en) * 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
DE19621177A1 (en) 1996-05-24 1997-11-27 Basf Ag Carbohydrate derivatives and their synthesis on solid phase
US6103479A (en) * 1996-05-30 2000-08-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US20060141539A1 (en) * 1996-05-30 2006-06-29 Taylor D L Miniaturized cell array methods and apparatus for cell-based screening
SE9602545L (en) * 1996-06-25 1997-12-26 Michael Mecklenburg Method of discriminating complex biological samples
US20050069923A1 (en) * 1996-07-08 2005-03-31 Mullis Kary Banks Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus
NZ333907A (en) 1996-07-08 2000-09-29 Burstein Lab Inc Cleavable optically detectable elements on substrate for microanalysis of chemical species
US6342349B1 (en) 1996-07-08 2002-01-29 Burstein Technologies, Inc. Optical disk-based assay devices and methods
US20050214827A1 (en) * 1996-07-08 2005-09-29 Burstein Technologies, Inc. Assay device and method
US6331275B1 (en) 1996-07-08 2001-12-18 Burstein Technologies, Inc. Spatially addressable, cleavable reflective signal elements, assay device and method
US6391550B1 (en) * 1996-09-19 2002-05-21 Affymetrix, Inc. Identification of molecular sequence signatures and methods involving the same
US7094609B2 (en) * 1996-09-20 2006-08-22 Burstein Technologies, Inc. Spatially addressable combinatorial chemical arrays in encoded optical disk format
NZ335453A (en) 1996-12-12 2001-07-27 Prolume Ltd Microelectronic device with microlocations including photodetector for detecting bioluminescence
US5773308A (en) * 1997-02-10 1998-06-30 The United States Of America As Represented By The Secretary Of The Navy Photoactivatable o-nitrobenzyl polyethylene glycol-silane for the production of patterned biomolecular arrays
WO1998035707A1 (en) 1997-02-18 1998-08-20 Thomas Jefferson University Compositions that bind to pancreatic cancer cells and methods of using the same
PL335226A1 (en) 1997-02-21 2000-04-10 Burstein Lab Gene sequencer and related methods
US5837860A (en) * 1997-03-05 1998-11-17 Molecular Tool, Inc. Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds
JP4313861B2 (en) * 1997-08-01 2009-08-12 キヤノン株式会社 Manufacturing method of probe array
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6559296B2 (en) * 1997-08-29 2003-05-06 Olympus Optical Co., Ltd. DNA capillary
US6607878B2 (en) 1997-10-06 2003-08-19 Stratagene Collections of uniquely tagged molecules
WO1999019510A1 (en) * 1997-10-10 1999-04-22 President And Fellows Of Harvard College Surface-bound, double-stranded dna protein arrays
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US20070166741A1 (en) * 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
DE69839350T2 (en) 1997-12-22 2009-06-04 Pioneer-Hi-Bred International, Inc. QTL MAPPING OF POPULATIONS IN PLANT BREEDING
US6087102A (en) * 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6303848B1 (en) 1998-01-16 2001-10-16 Large Scale Biology Corporation Method for conferring herbicide, pest, or disease resistance in plant hosts
US20020164585A1 (en) * 1998-01-16 2002-11-07 Sean Chapman Method for enhancing RNA or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids
US20030166169A1 (en) * 1998-01-16 2003-09-04 Padgett Hal S. Method for constructing viral nucleic acids in a cell-free manner
US20030027173A1 (en) * 1998-01-16 2003-02-06 Della-Cioppa Guy Method of determining the function of nucleotide sequences and the proteins they encode by transfecting the same into a host
US6426185B1 (en) 1998-01-16 2002-07-30 Large Scale Biology Corporation Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation
US6297010B1 (en) * 1998-01-30 2001-10-02 Genzyme Corporation Method for detecting and identifying mutations
US6150102A (en) * 1998-02-03 2000-11-21 Lucent Technologies Inc. Method of generating nucleic acid oligomers of known composition
US6537747B1 (en) 1998-02-03 2003-03-25 Lucent Technologies Inc. Data transmission using DNA oligomers
US6741956B1 (en) 1998-02-03 2004-05-25 Lucent Technologies Inc. Analog computation using hybridization-capable oligomers
AU2583899A (en) 1998-02-04 1999-08-23 Invitrogen Corporation Microarrays and uses therefor
US5994079A (en) 1998-02-06 1999-11-30 Digene Corporation Direct detection of RNA mediated by reverse transcriptase lacking RNAse H function
US7399589B2 (en) * 1998-02-06 2008-07-15 Digene Corporation Immunological detection of RNA:DNA hybrids on microarrays
US20040035690A1 (en) * 1998-02-11 2004-02-26 The Regents Of The University Of Michigan Method and apparatus for chemical and biochemical reactions using photo-generated reagents
CA2319587C (en) * 1998-02-11 2004-09-21 University Of Houston Method and apparatus for chemical and biochemical reactions using photo-generated reagents
CA2321070C (en) * 1998-02-23 2010-04-06 Wisconsin Alumni Research Foundation Method and apparatus for synthesis of arrays of dna probes
US6087103A (en) * 1998-03-04 2000-07-11 Lifespan Biosciences, Inc. Tagged ligand arrays for identifying target-ligand interactions
AU3217599A (en) * 1998-03-31 1999-10-18 Genzyme Corporation Methods for the diagnosis and treatment of lung cancer
US6048695A (en) * 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6271957B1 (en) * 1998-05-29 2001-08-07 Affymetrix, Inc. Methods involving direct write optical lithography
EP1112377A4 (en) * 1998-06-22 2004-11-10 Univ California Nucleic acid-coupled colorimetric analyte detectors
US6235473B1 (en) 1998-07-02 2001-05-22 Orchid Biosciences, Inc. Gene pen devices for array printing
US6897073B2 (en) * 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US20020119579A1 (en) * 1998-07-14 2002-08-29 Peter Wagner Arrays devices and methods of use thereof
US20030138973A1 (en) * 1998-07-14 2003-07-24 Peter Wagner Microdevices for screening biomolecules
US6682942B1 (en) 1998-07-14 2004-01-27 Zyomyx, Inc. Microdevices for screening biomolecules
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6576478B1 (en) 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
WO2000004193A1 (en) 1998-07-20 2000-01-27 Yale University Method for detecting nucleic acids using target-mediated ligation of bipartite primers
CA2338401A1 (en) * 1998-07-21 2000-02-03 Burstein Laboratories, Inc Optical disc-based assay devices and methods
US6461812B2 (en) * 1998-09-09 2002-10-08 Agilent Technologies, Inc. Method and multiple reservoir apparatus for fabrication of biomolecular arrays
EP1114184A2 (en) * 1998-09-15 2001-07-11 Yale University Molecular cloning using rolling circle amplification
CA2342837A1 (en) 1998-09-15 2000-03-23 Yale University Artificial long terminal repeat vectors
US6475440B1 (en) 1998-09-16 2002-11-05 Clontech Laboratories, Inc. Applicator for use in deposition of fluid samples onto a substrate surface
US6203989B1 (en) 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
US6262216B1 (en) 1998-10-13 2001-07-17 Affymetrix, Inc. Functionalized silicon compounds and methods for their synthesis and use
US6541203B2 (en) * 1998-11-23 2003-04-01 President And Fellows Of Harvard College Detecting structural or synthetic information about chemical compounds
US6441152B1 (en) * 1998-12-08 2002-08-27 Boston Probes, Inc. Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
AU2877000A (en) * 1999-02-10 2000-08-29 University Of Maryland Photo-induced nucleic acid hybridization
EP2133426A3 (en) 1999-03-11 2010-04-14 Arborgen, Llc Compositions and methods for the modification of gene transcription
US7014994B1 (en) 1999-03-19 2006-03-21 Cornell Research Foundation,Inc. Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process
US6506594B1 (en) * 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7518034B2 (en) * 1999-03-25 2009-04-14 Arborgen Llc Compositions and methods for the modification of gene expression
US6824866B1 (en) 1999-04-08 2004-11-30 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
US6518056B2 (en) * 1999-04-27 2003-02-11 Agilent Technologies Inc. Apparatus, systems and method for assaying biological materials using an annular format
CA2373026C (en) * 1999-05-04 2011-05-03 Large Scale Biology Corporation Viral expression vectors
US6824987B1 (en) * 1999-05-11 2004-11-30 President And Fellows Of Harvard College Small molecule printing
PT1214594E (en) * 1999-05-14 2006-11-30 Iris Biotechnologies Inc Reversible immobilization of ligands onto metal surfaces, their preparation and use in biochemical applications
US6485690B1 (en) 1999-05-27 2002-11-26 Orchid Biosciences, Inc. Multiple fluid sample processor and system
WO2000079006A1 (en) * 1999-06-17 2000-12-28 Fred Hutchinson Cancer Research Center Oligonucleotide arrays for high resolution hla typing
US6346423B1 (en) 1999-07-16 2002-02-12 Agilent Technologies, Inc. Methods and compositions for producing biopolymeric arrays
US7144700B1 (en) * 1999-07-23 2006-12-05 Affymetrix, Inc. Photolithographic solid-phase polymer synthesis
CA2317179A1 (en) * 1999-09-01 2001-03-01 Affymetrix, Inc. Macromolecular arrays on polymeric brushes and methods for preparing the same
KR100858465B1 (en) 1999-09-10 2008-09-16 제론 코포레이션 Oligonucleotide n3'?p5' thiophosphoramidates: their synthesis and use
AU1075701A (en) * 1999-10-08 2001-04-23 Protogene Laboratories, Inc. Method and apparatus for performing large numbers of reactions using array assembly
US6171797B1 (en) 1999-10-20 2001-01-09 Agilent Technologies Inc. Methods of making polymeric arrays
WO2001036442A1 (en) * 1999-11-17 2001-05-25 Jiuping Ji Simultaneous detection of hbv, hcv and hiv in plasma samples using a multiplex capture assay
NZ539430A (en) 1999-12-10 2006-09-29 Invitrogen Corp Use of multiple recombination sites with unique specificity in recombinational cloning
DE19962803A1 (en) * 1999-12-23 2001-07-05 Basf Ag Process and device for mask-free production of biopolymers
US6800439B1 (en) 2000-01-06 2004-10-05 Affymetrix, Inc. Methods for improved array preparation
US6833450B1 (en) 2000-03-17 2004-12-21 Affymetrix, Inc. Phosphite ester oxidation in nucleic acid array preparation
US20050119473A1 (en) * 2000-03-17 2005-06-02 Affymetrix, Inc. Phosphite ester oxidation in nucleic acid array preparation
US6806361B1 (en) 2000-03-17 2004-10-19 Affymetrix, Inc. Methods of enhancing functional performance of nucleic acid arrays
DE60142228D1 (en) 2000-03-27 2010-07-08 Univ Jefferson COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS FROM THE DIGESTIVE CHANNEL
IL151865A0 (en) * 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
US7157564B1 (en) 2000-04-06 2007-01-02 Affymetrix, Inc. Tag nucleic acids and probe arrays
AU2001259241A1 (en) * 2000-04-26 2001-11-07 Arcturus Engineering, Inc. Laser capture microdissection (lcm) extraction device and device carrier and method for post-lcm fluid processing
US8399383B2 (en) * 2000-05-04 2013-03-19 Yale University Protein chips for high throughput screening of protein activity
US7005259B1 (en) * 2000-06-01 2006-02-28 Affymetrix, Inc. Methods for array preparation using substrate rotation
AU6795201A (en) * 2000-06-20 2002-01-02 Genesis Res & Dev Corp Ltd Nucleic acid sequences and methods for the modification of plant gene expression
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
EP1311839B1 (en) 2000-06-21 2006-03-01 Bioarray Solutions Ltd Multianalyte molecular analysis using application-specific random particle arrays
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
US7270954B1 (en) 2000-06-30 2007-09-18 Iris Biotechnologies, Inc. Hybridization of target DNA with immobilized nucleic acid analogs
US7091033B2 (en) * 2000-07-21 2006-08-15 Phase-1 Molecular Toxicology, Inc. Array of toxicologically relevant canine genes and uses thereof
DE10040857A1 (en) 2000-08-11 2002-02-28 Jens P Fuerste Nucleic acid library or protein or peptide library
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
WO2002013855A2 (en) 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6900013B1 (en) 2000-08-25 2005-05-31 Aviva Biosciences Corporation Methods and compositions for identifying nucleic acid molecules using nucleolytic activities and hybridization
EP1387894A4 (en) * 2000-08-24 2006-10-11 Aviva Biosciences Corp Methods and compositions for identifying nucleic acid molecules using nucleolytic activities and hybridization
US20020164634A1 (en) * 2000-08-26 2002-11-07 Perlegen Sciences, Inc. Methods for reducing complexity of nucleic acid samples
CA2421732A1 (en) * 2000-09-11 2002-03-14 Affymetrix, Inc. Photocleavable protecting groups
AU2001292728A1 (en) * 2000-09-18 2002-03-26 Thomas Jefferson University Compositions and methods for identifying and targeting stomach and esophageal cancer cells
US20020037359A1 (en) * 2000-09-25 2002-03-28 Mutz Mitchell W. Focused acoustic energy in the preparation of peptide arrays
US6849409B2 (en) * 2000-10-16 2005-02-01 Axxima Pharmaceuticals Ag Cellular kinases involved in Cytomegalovirus infection and their inhibition
US7001740B2 (en) * 2000-11-08 2006-02-21 Surface Logix, Inc. Methods of arraying biological materials using peelable and resealable devices
US6967074B2 (en) * 2000-11-08 2005-11-22 Surface Logix, Inc. Methods of detecting immobilized biomolecules
US7439056B2 (en) 2000-11-08 2008-10-21 Surface Logix Inc. Peelable and resealable devices for arraying materials
US7371563B2 (en) * 2000-11-08 2008-05-13 Surface Logix, Inc. Peelable and resealable devices for biochemical assays
US7351575B2 (en) * 2000-11-08 2008-04-01 Surface Logix, Inc. Methods for processing biological materials using peelable and resealable devices
US6803205B2 (en) * 2000-11-08 2004-10-12 Surface Logix, Inc. Methods of measuring enzyme activity using peelable and resealable devices
AU2002228872A1 (en) * 2000-11-09 2002-05-21 Burstein Technologies, Inc. Disc drive system and methods for use with bio-discs
GB0029590D0 (en) * 2000-12-05 2001-01-17 Univ Heriot Watt Bio-strings
AU2002241851A1 (en) * 2001-01-11 2002-07-24 Burstein Technologies, Inc. Optical disc analysis system including related methods for biological and medical imaging
WO2002062957A2 (en) * 2001-02-07 2002-08-15 Invitrogen Corporation Ter sites and ter binding proteins
WO2002099982A2 (en) * 2001-03-01 2002-12-12 Illumina, Inc. Methods for improving signal detection from an array
FR2822476B1 (en) 2001-03-23 2004-04-02 Aventis Pharma Sa METHODS OF PURIFICATION AND DETECTION OF TARGET SEQUENCES OF DOUBLE-STRANDED DNA BY TRIPLE-HELICE INTERACTION
AU2002247765B2 (en) * 2001-03-28 2007-04-26 Clondiag Chip Technologies Gmbh Device for referencing fluorescence signals
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US7115726B2 (en) * 2001-03-30 2006-10-03 Perlegen Sciences, Inc. Haplotype structures of chromosome 21
EP1249499A1 (en) * 2001-04-10 2002-10-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method and device for the determination and selection of molecule-molecule interactions
WO2002097109A2 (en) * 2001-05-25 2002-12-05 Invitrogen Corporation Compositions and methods for extension of nucleic acids
US20070184436A1 (en) * 2001-06-07 2007-08-09 Joel Myerson Generic capture probe arrays
US20030013109A1 (en) * 2001-06-21 2003-01-16 Ballinger Clinton T. Hairpin sensors using quenchable fluorescing agents
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
EP1925672A1 (en) 2001-06-22 2008-05-28 Syngeta Participations AG Abiotic stress responsive polynucleotides and polypeptides
US6703235B2 (en) * 2001-06-25 2004-03-09 Board Of Regents, The University Of Texas System Complex multicellular assemblies ex vivo
US7221632B2 (en) * 2001-07-12 2007-05-22 Burstein Technologies, Inc. Optical disc system and related detecting methods for analysis of microscopic structures
US20030143612A1 (en) * 2001-07-18 2003-07-31 Pointilliste, Inc. Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
CN1556924A (en) * 2001-07-20 2004-12-22 ̹�� Optical analysis disc and related drive assembly for performing interactive centrifugation
WO2003062783A2 (en) * 2001-07-20 2003-07-31 North Carolina State University Light addressable electrochemical detection of duplex structures
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
JP2005511012A (en) 2001-08-10 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム Human cDNA and protein and uses thereof
US20030165918A1 (en) * 2001-08-17 2003-09-04 Fuji Photo Film Co., Ltd. Method for detecting nucleic acid
US20080026367A9 (en) * 2001-08-17 2008-01-31 Perlegen Sciences, Inc. Methods for genomic analysis
US20030040129A1 (en) * 2001-08-20 2003-02-27 Shah Haresh P. Binding assays using magnetically immobilized arrays
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
US20030044798A1 (en) * 2001-08-31 2003-03-06 Lefkowitz Steven M. Methods for generating ligand arrays via deposition of ligands onto olefin displaying substrates, and arrays produced thereby
US20050147984A1 (en) * 2001-08-31 2005-07-07 Clondiag Chip Technologies Gmbh Interaction detection on several probe arrays
US6974671B1 (en) 2001-09-12 2005-12-13 Salk Institute For Biological Studies Methods for indentifying compounds that modulate gluconeogenesis through the binding of CREB to the PGC-1 promoter
US20060188875A1 (en) * 2001-09-18 2006-08-24 Perlegen Sciences, Inc. Human genomic polymorphisms
US20040053232A1 (en) * 2001-10-05 2004-03-18 Perlegen Sciences, Inc. Haplotype structures of chromosome 21
DE10149684B4 (en) * 2001-10-09 2005-02-17 Clondiag Chip Technologies Gmbh Device for holding a substance library carrier
US20040002073A1 (en) 2001-10-15 2004-01-01 Li Alice Xiang Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection
EP1437368B8 (en) * 2001-10-16 2014-01-08 Federalnoe Gosudarstvennoe Byudzhetnoe Uchrezhdenie Nauki Institut Molekulyarnoi Biologi Im. V.A. Engelgardta Rossiiskoi Akademii Nauk Composition for polymerising immobilisation of biological molecules and method for producing said composition
US20040014064A1 (en) * 2001-10-31 2004-01-22 Brissette William H. Therapeutics and diagnostics for disorders of erythropoiesis
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
AU2002364894A1 (en) * 2001-11-09 2003-06-30 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin
US20080094974A1 (en) * 2001-11-09 2008-04-24 Burstein Technologies, Inc. Optical disc system and related detecting methods for analysis of microscopic structures
US20040067512A1 (en) * 2001-11-09 2004-04-08 Neurogenetics, Inc. Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
CA2469403C (en) 2001-12-05 2015-06-02 Jonathan Mark Boutell Protein arrays for allelic variants and uses thereof
CN1281324C (en) * 2001-12-19 2006-10-25 阿菲梅特里克斯公司 Manufacturing process for array plate assembly
US7011945B2 (en) * 2001-12-21 2006-03-14 Eastman Kodak Company Random array of micro-spheres for the analysis of nucleic acids
CN100343670C (en) * 2001-12-21 2007-10-17 皇家飞利浦电子股份有限公司 Sensor and method for measuring the areal density of magnetic nanoparticles on a micro-array
CA2471658A1 (en) * 2001-12-26 2003-07-10 Canon Kabushiki Kaisha Probe medium and method for fixing probe on a substrate
WO2003060668A2 (en) * 2002-01-14 2003-07-24 Burstein Technologies, Inc. Method and apparatus for visualizing data
DE10201463B4 (en) 2002-01-16 2005-07-21 Clondiag Chip Technologies Gmbh Reaction vessel for performing array method
JP2005516336A (en) * 2002-01-28 2005-06-02 バースタイン テクノロジーズ,インコーポレイティド Method and apparatus for logical triggering
US20050002827A1 (en) * 2002-01-29 2005-01-06 Mcintyre Kevin Robert Optical discs including equi-radial and/or spiral analysis zones and related disc drive systems and methods
US20040053264A1 (en) * 2002-02-01 2004-03-18 Park Sung Sup Clinical panel assay using DNA chips
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
CA2476309A1 (en) * 2002-02-15 2003-08-28 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
US7108891B2 (en) * 2002-03-07 2006-09-19 Eastman Kodak Company Random array of microspheres
US6916620B2 (en) * 2002-03-15 2005-07-12 Eastman Kodak Company Random array of micro-spheres for the analysis of nucleic acid using enzyme digestion
US20030186302A1 (en) * 2002-03-29 2003-10-02 Yixin Wang Colorectal cancer diagnostics
US20030194709A1 (en) * 2002-04-10 2003-10-16 Xing Yang Hydrophobic zone device
US20040023275A1 (en) * 2002-04-29 2004-02-05 Perlegen Sciences, Inc. Methods for genomic analysis
ATE534035T1 (en) 2002-05-08 2011-12-15 Northwest Biotherapeutics Inc QUALITY TESTS FOR ANTIGEN-PRESENTING CELLS
US7011971B2 (en) * 2002-06-03 2006-03-14 Eastman Kodak Company Method of making random array of microspheres using enzyme digestion
US6730515B2 (en) 2002-06-11 2004-05-04 Eastman Kodak Company Micro-array calibration means
US7135343B2 (en) * 2002-06-17 2006-11-14 Agilent Technologies, Inc. Biomolecule resistant and their methods of use in assays
US20030231986A1 (en) * 2002-06-18 2003-12-18 Eastman Kodak Company Micro-array identification means
US7332273B2 (en) 2002-06-20 2008-02-19 Affymetrix, Inc. Antireflective coatings for high-resolution photolithographic synthesis of DNA arrays
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
AU2003257109A1 (en) * 2002-08-05 2004-02-23 Invitrogen Corporation Compositions and methods for molecular biology
US20050233473A1 (en) * 2002-08-16 2005-10-20 Zyomyx, Inc. Methods and reagents for surface functionalization
US20050118616A1 (en) * 2002-08-16 2005-06-02 Kawashima Tadashi R. Amplification of target nucleotide sequence without polymerase chain reaction
US7157228B2 (en) * 2002-09-09 2007-01-02 Bioarray Solutions Ltd. Genetic analysis and authentication
AU2003270898A1 (en) * 2002-09-27 2004-04-19 Nimblegen Systems, Inc. Microarray with hydrophobic barriers
US20040110212A1 (en) * 2002-09-30 2004-06-10 Mccormick Mark Microarrays with visual alignment marks
AU2003301825A1 (en) * 2002-10-31 2004-06-07 Pfizer Products, Inc. Panels of molecular targets differentially expressed during cd8+ t-cell priming
US20040086892A1 (en) * 2002-11-06 2004-05-06 Crothers Donald M. Universal tag assay
US7526114B2 (en) 2002-11-15 2009-04-28 Bioarray Solutions Ltd. Analysis, secure access to, and transmission of array images
EP1565578A4 (en) * 2002-11-18 2007-11-07 Panomics Inc Rnai-based sensors, caged interfering rnas, and methods of use thereof
DE10253966B4 (en) * 2002-11-19 2005-03-24 Clondiag Chip Technologies Gmbh Microarray-based method for the amplification and detection of nucleic acids in a continuous process
AU2003302472B2 (en) * 2002-11-22 2010-10-21 The Johns Hopkins University Target for therapy of cognitive impairment
US20040106114A1 (en) * 2002-12-02 2004-06-03 Eastman Kodak Company Simplified detection process for colored bead random microarrays
US20040109045A1 (en) * 2002-12-06 2004-06-10 Eastman Kodak Company Print head for micro-deposition of bio-molecules
US20040110136A1 (en) * 2002-12-09 2004-06-10 Eastman Kodak Company Micro-array calibration system and method
US20040120859A1 (en) * 2002-12-20 2004-06-24 Kocher Thomas E. Biomolecular micro-deposition system
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6977153B2 (en) * 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
US20040180369A1 (en) * 2003-01-16 2004-09-16 North Carolina State University Photothermal detection of nucleic acid hybridization
ATE410450T1 (en) * 2003-01-22 2008-10-15 Bionanophotonics As LIGHT-INDUCED IMMOBILIZATION
WO2004071436A2 (en) * 2003-02-10 2004-08-26 Thomas Jefferson University The use of gcc ligands
US7166451B1 (en) * 2003-02-24 2007-01-23 The Ohio State University Immobilization of enzyme on a fibrous matrix
US20090124514A1 (en) * 2003-02-26 2009-05-14 Perlegen Sciences, Inc. Selection probe amplification
US20060183132A1 (en) * 2005-02-14 2006-08-17 Perlegen Sciences, Inc. Selection probe amplification
US20040235019A1 (en) * 2003-03-06 2004-11-25 Agouron Pharmaceuticals, Inc. Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand
JP2004279196A (en) * 2003-03-14 2004-10-07 Dainippon Printing Co Ltd Substrate for bio-micro-array and bio-micro-array
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
DE10315074A1 (en) * 2003-04-02 2004-10-14 Clondiag Chip Technologies Gmbh Device for the duplication and detection of nucleic acids
US7348420B2 (en) 2003-04-25 2008-03-25 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
MXPA05011404A (en) * 2003-04-25 2006-05-31 Johnson & Johnson Preservation of rna in a biological sample.
US20040248323A1 (en) * 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
WO2005000098A2 (en) 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
EP2319863A1 (en) 2003-06-23 2011-05-11 North Carolina State University Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof
US7642064B2 (en) * 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
ATE437369T1 (en) * 2003-06-24 2009-08-15 Ventana Med Syst Inc ENZYME-CATALYzed METAL DEPOSITION FOR ENHANCED IN-SITU DETECTION OF IMMUNOHISTOLOGICAL EPITOPES AND NUCLEIC ACID SEQUENCES
US7034941B2 (en) * 2003-06-26 2006-04-25 Eastman Kodak Company Color detection using spectroscopic imaging and processing in random array of microspheres
US6947142B2 (en) * 2003-06-26 2005-09-20 Eastman Kodak Company Color detection in random array of microspheres
US20050019944A1 (en) * 2003-07-23 2005-01-27 Eastman Kodak Company Colorable microspheres for DNA and protein microarray
US20050019745A1 (en) * 2003-07-23 2005-01-27 Eastman Kodak Company Random array of microspheres
US6914106B2 (en) * 2003-07-23 2005-07-05 Eastman Kodak Company Polymer microspheres containing latent colorants and method of preparation
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
US20050059054A1 (en) 2003-07-25 2005-03-17 Richard Conrad Methods and compositions for preparing RNA from a fixed sample
US6995206B2 (en) * 2003-07-28 2006-02-07 Hewlett-Packard Development Company, L.P. Methods of preparing latex particulates with reactive functional groups
US20050100911A1 (en) * 2003-08-06 2005-05-12 Perlegen Sciences, Inc. Methods for enriching populations of nucleic acid samples
US7927796B2 (en) 2003-09-18 2011-04-19 Bioarray Solutions, Ltd. Number coding for identification of subtypes of coded types of solid phase carriers
WO2005031305A2 (en) 2003-09-22 2005-04-07 Bioarray Solutions, Ltd. Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
US7563569B2 (en) 2003-10-28 2009-07-21 Michael Seul Optimization of gene expression analysis using immobilized capture probes
JP2007509629A (en) 2003-10-29 2007-04-19 バイオアレイ ソリューションズ リミテッド Complex nucleic acid analysis by cleavage of double-stranded DNA
WO2005042783A1 (en) * 2003-10-30 2005-05-12 North Carolina State University Temperature-jump enhanced electrochemical detection of nucleic acid hybridization
US20100000881A1 (en) * 2003-10-30 2010-01-07 North Carolina State University Electrochemical detection of nucleic acid hybridization
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
WO2005049848A2 (en) * 2003-11-12 2005-06-02 Geneohm Sciences, Inc. Nucleic acid hybridization methods
US20050106712A1 (en) * 2003-11-14 2005-05-19 Eastman Kodak Company Yellow low fluorescence dye for coated optical bead random array DNA analysis
US20050106574A1 (en) * 2003-11-14 2005-05-19 Eastman Kodak Company Magenta low fluorescence dye for coated optical bead random array DNA analysis
US20050106711A1 (en) * 2003-11-14 2005-05-19 Eastman Kodak Company Cyan low fluorescence dye for coated optical bead random array DNA analysis
DK1709198T3 (en) 2003-11-26 2013-09-02 Advandx Inc Peptide Nucleic Acid Probes for the Analysis of Certain Staphylococcus Species
JP2007512838A (en) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション Nucleic acid molecules containing recombination sites and methods of use thereof
CA2497324A1 (en) 2004-02-17 2005-08-17 Affymetrix, Inc. Methods for fragmenting and labelling dna
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7459289B2 (en) 2004-03-08 2008-12-02 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor
EP1720015A1 (en) * 2004-03-17 2006-11-08 Matsushita Electric Industrial Co., Ltd. Process for producing biochip, probe solution, and biochip
US7919277B2 (en) 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
US20050244984A1 (en) * 2004-04-28 2005-11-03 Parker Russell A Methods and compositions for calibrating chemical array readers
DE102005052713A1 (en) 2005-11-04 2007-05-16 Clondiag Chip Tech Gmbh Apparatus and method for detecting molecular interactions
DE102004022263A1 (en) 2004-05-06 2005-12-15 Clondiag Chip Technologies Gmbh Apparatus and method for detecting molecular interactions
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
US20060009038A1 (en) * 2004-07-12 2006-01-12 International Business Machines Corporation Processing for overcoming extreme topography
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
US20060073506A1 (en) 2004-09-17 2006-04-06 Affymetrix, Inc. Methods for identifying biological samples
US7314542B2 (en) * 2004-09-23 2008-01-01 Nanogen, Inc. Methods and materials for optimization of electronic transportation and hybridization reactions
EP1645640B1 (en) 2004-10-05 2013-08-21 Affymetrix, Inc. Method for detecting chromosomal translocations
CN101080487B (en) 2004-10-07 2012-11-14 阿戈斯治疗公司 Mature dendritic cell compositions and methods for culturing same
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
EP1652580A1 (en) 2004-10-29 2006-05-03 Affymetrix, Inc. High throughput microarray, package assembly and methods of manufacturing arrays
DE102004056735A1 (en) 2004-11-09 2006-07-20 Clondiag Chip Technologies Gmbh Device for performing and analyzing microarray experiments
EP2281887A1 (en) 2004-11-12 2011-02-09 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
CA2589782A1 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
US7547775B2 (en) * 2004-12-31 2009-06-16 Affymetrix, Inc. Parallel preparation of high fidelity probes in an array format
US8338093B2 (en) * 2004-12-31 2012-12-25 Affymetrix, Inc. Primer array synthesis and validation
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
JP2008527996A (en) * 2005-01-25 2008-07-31 スカイ、ジェネティクス、インク Nucleic acids for apoptosis of cancer cells
WO2006083751A2 (en) * 2005-01-31 2006-08-10 Pacific Biosciences Of California, Inc. Use of reversible extension terminator in nucleic acid sequencing
US20060194215A1 (en) * 2005-02-28 2006-08-31 Kronick Mel N Methods, reagents and kits for reusing arrays
US20060257902A1 (en) * 2005-03-25 2006-11-16 Ambion, Inc. Methods and compositions for depleting abundant RNA transcripts
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA
WO2006108135A2 (en) * 2005-04-04 2006-10-12 Veridex, Llc Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways
US20060229819A1 (en) * 2005-04-12 2006-10-12 Eastman Kodak Company Method for imaging an array of microspheres
US20060228720A1 (en) * 2005-04-12 2006-10-12 Eastman Kodak Company Method for imaging an array of microspheres
US20060228719A1 (en) * 2005-04-12 2006-10-12 Eastman Kodak Company Method for imaging an array of microspheres using specular illumination
EP2360278A1 (en) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnostic for lung disorders using class prediction
CN101198689A (en) 2005-04-15 2008-06-11 北卡罗来纳州大学 Methods and compositions to modulate adhesion and stress tolerance in bacteria
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US8486629B2 (en) 2005-06-01 2013-07-16 Bioarray Solutions, Ltd. Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
WO2007000163A1 (en) * 2005-06-27 2007-01-04 Bionanophotonics A/S Immobilisation of polypeptides by irradiation
US7666584B2 (en) * 2005-09-01 2010-02-23 Philadelphia Health & Education Coporation Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
EP2402758B1 (en) 2005-09-19 2014-09-10 Janssen Diagnostics, LLC Methods and uses for identifying the origin of a carcinoma of unknown primary origin
US7763423B2 (en) * 2005-09-30 2010-07-27 Pacific Biosciences Of California, Inc. Substrates having low density reactive groups for monitoring enzyme activity
WO2007047408A2 (en) * 2005-10-12 2007-04-26 Pathologica, Llc. Promac signature application
US7634363B2 (en) 2005-12-07 2009-12-15 Affymetrix, Inc. Methods for high throughput genotyping
EP1960547A2 (en) 2005-12-08 2008-08-27 Novartis AG Effects of inhibitors of fgfr3 on gene transcription
US20070141584A1 (en) * 2005-12-20 2007-06-21 Roberts Douglas N Methods for assessment of native chromatin on microarrays
US20070255054A1 (en) * 2005-12-30 2007-11-01 Affymetrix, Inc. Oligonucleotide synthesis with intermittent and post synthetic oxidation
JP2009522576A (en) * 2006-01-03 2009-06-11 プレジデント アンド フェローズ オブ ハーバード カレッジ Small molecule printing
ES2644499T3 (en) * 2006-01-17 2017-11-29 Somalogic, Inc. Kits comprising aptamers
EP1986661B1 (en) 2006-02-08 2018-08-29 Genzyme Corporation Gene therapy for niemann-pick disease type a
US20090061454A1 (en) 2006-03-09 2009-03-05 Brody Jerome S Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
BRPI0709396A2 (en) * 2006-03-13 2011-07-05 Veridex Llc primary cell propagation
WO2007121054A2 (en) * 2006-03-27 2007-10-25 Sky Genetics, Inc. Nucleic acids for apoptosis of cancer cells
US8975216B2 (en) 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
US20080050747A1 (en) * 2006-03-30 2008-02-28 Pacific Biosciences Of California, Inc. Articles having localized molecules disposed thereon and methods of producing and using same
EP2029780A4 (en) * 2006-06-16 2010-03-31 Pacific Biosciences California Controlled initiation of primer extension
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
AU2007299828C1 (en) 2006-09-19 2014-07-17 Interpace Diagnostics, Llc MicroRNAs differentially expressed in pancreatic diseases and uses thereof
JP2010510964A (en) 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド MiR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292 as targets for therapeutic intervention Genes and pathways regulated by 3p
EP2069377A4 (en) 2006-09-27 2009-11-11 Univ California Methods and compositions for the treatment of skin diseases and disorders
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
DE102006035393A1 (en) 2006-11-02 2008-05-15 Signature Diagnostics Ag Prognostic markers for the classification of the three-year progression-free survival of patients with colon carcinoma based on expression profiles of biological samples
DE102006035392A1 (en) 2006-11-02 2008-10-16 Signature Diagnostics Ag Prognostic markers for the prediction of five-year progression-free survival of patients with colon carcinoma based on expression profiles of biological samples
DE102006035388A1 (en) * 2006-11-02 2008-05-15 Signature Diagnostics Ag Prognostic markers for the classification of colon carcinomas based on expression profiles of biological samples
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
AU2007333109A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro RNAs
US20080182328A1 (en) * 2006-12-19 2008-07-31 The Burnham Institute Mammalian extraembryonic endoderm cells and methods of isolation
US20100248975A1 (en) * 2006-12-29 2010-09-30 Gunjan Tiwari Fluorogenic peptide substrate arrays for highly multiplexed, real-time monitoring of kinase activities
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) * 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7964356B2 (en) * 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) * 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7572990B2 (en) * 2007-03-30 2009-08-11 Intermec Ip Corp. Keypad overlay membrane
US20080274458A1 (en) * 2007-05-01 2008-11-06 Latham Gary J Nucleic acid quantitation methods
US8200440B2 (en) * 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
DE102007031526B4 (en) 2007-07-06 2010-07-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Use of an anode in a fuel cell for the oxidation of ethanol and / or at least one C3 to C10-containing alcohol
EP2185195A2 (en) * 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
EP2195451A4 (en) * 2007-08-28 2011-01-19 Merck Sharp & Dohme Expression profiles of biomarker genes in notch mediated cancers
DK2548962T3 (en) 2007-09-19 2016-04-11 Applied Biosystems Llc Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
DE102007062154A1 (en) 2007-12-21 2009-06-25 Emc Microcollections Gmbh Process for the preparation and use of stochastically arranged arrays of test substances
US20090192045A1 (en) * 2008-01-22 2009-07-30 Yuqiu Jiang Molecular staging of stage ii and iii colon cancer and prognosis
US20090233809A1 (en) * 2008-03-04 2009-09-17 Affymetrix, Inc. Resequencing methods for identification of sequence variants
CN101918597B (en) 2008-03-11 2013-09-18 国立癌中心 Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using SNP array
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2010096036A2 (en) 2008-05-14 2010-08-26 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
CA2742324A1 (en) 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
JP2012508577A (en) 2008-11-12 2012-04-12 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Method and system for using exosomes to determine phenotype
US20100161607A1 (en) 2008-12-22 2010-06-24 Jasjit Singh System and method for analyzing genome data
ES2805347T3 (en) 2009-02-11 2021-02-11 Caris Mpi Inc Molecular profiling of tumors
WO2010096658A1 (en) 2009-02-19 2010-08-26 The Cleveland Clinic Foundation Corin as a marker for heart failure
WO2010101627A2 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
EP3255146B1 (en) 2009-03-16 2019-05-15 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
CN102449143B (en) 2009-03-31 2017-11-14 Atyr医药公司 Include the composition and method of the aspartoyl tRNA synzyme with unconventional bioactivity
WO2010125566A2 (en) 2009-04-27 2010-11-04 Technion Research And Development Foundation Ltd. Markers for cancer detection
US20100298171A1 (en) * 2009-05-22 2010-11-25 Affymetrix, Inc. Apparatus for polymer synthesis
US8632975B2 (en) 2009-06-05 2014-01-21 Life Technologies Corporation Nucleotide transient binding for sequencing methods
US8501406B1 (en) 2009-07-14 2013-08-06 Pacific Biosciences Of California, Inc. Selectively functionalized arrays
US9771618B2 (en) * 2009-08-19 2017-09-26 Bioarray Genetics, Inc. Methods for treating breast cancer
AU2010315400B2 (en) 2009-10-27 2016-07-21 Caris Mpi, Inc. Molecular profiling for personalized medicine
AU2010324594B2 (en) 2009-11-30 2016-09-15 Caris Life Sciences Switzerland Holdings Gmbh Methods and systems for isolating, storing, and analyzing vesicles
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US20110143966A1 (en) * 2009-12-15 2011-06-16 Affymetrix, Inc. Surface Modifications and Methods for their Synthesis and Use
FR2954349A1 (en) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech SULFATASE SELECTIVELY MODIFYING GLYCOSAMINOGLYCANS
WO2011088226A2 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings Detection of gastrointestinal disorders
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
AU2011223527B2 (en) 2010-03-03 2014-11-13 Somalogic Operating Co., Inc. Aptamers to 4-1BB and their use in treating diseases and disorders
EP2542678B1 (en) 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
EP2556172A4 (en) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
JP6012591B2 (en) 2010-04-12 2016-10-26 ソマロジック, インコーポレイテッドSomaLogic, Inc. Aptamers to β-NGF and their use in the treatment of β-NGF mediated diseases and disorders
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
EP2563911B1 (en) 2010-04-28 2021-07-21 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
WO2011135459A2 (en) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
JP5976638B2 (en) 2010-05-03 2016-08-23 エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of arginyl tRNA synthetase
EP2566495B1 (en) 2010-05-03 2017-03-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
US9062302B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
WO2011146725A1 (en) 2010-05-19 2011-11-24 Bayer Healthcare Llc Biomarkers for a multikinase inhibitor
EP2388336A1 (en) 2010-05-19 2011-11-23 Signature Diagnostics AG Method and kits for diagnosing colorectal cancer
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103118694B (en) 2010-06-01 2016-08-03 Atyr医药公司 The discovery for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of lysyl-tRNA synzyme
WO2012005572A1 (en) 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
WO2012009711A2 (en) 2010-07-16 2012-01-19 Tocagen Inc. Retrovirus detection
US9029506B2 (en) 2010-08-25 2015-05-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases
BR112013012265A2 (en) 2010-11-17 2016-08-02 Asuragen Inc mirnas as biomarkers to distinguish benign from malignant thyroid neoplasms
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
EP3369828B1 (en) 2011-02-07 2020-07-15 The Governing Council Of The University Of Toronto Bioprobes and methods of use thereof
WO2012158238A2 (en) 2011-02-28 2012-11-22 University Of Iowa Research Foundation Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender
US8759036B2 (en) 2011-03-21 2014-06-24 Affymetrix, Inc. Methods for synthesizing pools of probes
JP2014510533A (en) 2011-03-28 2014-05-01 ノバルティス アーゲー Markers associated with cyclin-dependent kinase inhibitors
EP2520661A1 (en) 2011-05-02 2012-11-07 Rheinische Friedrich-Wilhelms-Universität Bonn Blood-based gene expression signatures in lung cancer
EP2527459A1 (en) 2011-05-02 2012-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Blood-based gene detection of non-small cell lung cancer
EP2710147A1 (en) 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
EP2524967A1 (en) 2011-05-19 2012-11-21 Signature Diagnostics AG Methods and kits for diagnosing colorectal cancer
EP2524968A1 (en) 2011-05-19 2012-11-21 Signature Diagnostics AG Methods and kits for diagnosing colorectal cancer
WO2012163541A1 (en) 2011-06-01 2012-12-06 Medical Prognosis Institute A/S Methods and devices for prognosis of cancer relapse
US9435812B2 (en) 2011-08-31 2016-09-06 Ventana Medical Systems, Inc. Expression of ETS related gene (ERG) and phosphatase and tensin homolog (PTEN) correlates with prostate cancer capsular penetration
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
WO2013063519A1 (en) 2011-10-26 2013-05-02 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
WO2013063544A1 (en) 2011-10-27 2013-05-02 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
CN106978487A (en) 2011-10-28 2017-07-25 米伦纽姆医药公司 Biomarkers of response to inhibitors of NEDD8 activating enzyme (NAE)
EP2776043B1 (en) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2856107C (en) 2011-11-18 2022-10-18 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
US8748097B1 (en) 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof
WO2013087789A1 (en) 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
CA2864300A1 (en) 2012-02-16 2013-08-22 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
EP2827882B1 (en) 2012-02-21 2020-04-08 Cytonics Corporation Systems, compositions, and methods for transplantation
EP2820174B1 (en) 2012-02-27 2019-12-25 The University of North Carolina at Chapel Hill Methods and uses for molecular tags
EP3321378B1 (en) 2012-02-27 2021-11-10 Becton, Dickinson and Company Compositions for molecular counting
CN104379764B (en) 2012-03-28 2018-04-06 私募蛋白质体公司 PDGF and VEGF fit and their purposes in the symptom for the treatment of PDGF and VEGF mediations
WO2014007623A1 (en) 2012-07-03 2014-01-09 Interna Technologies B.V. Diagnostic portfolio and its uses
EP3309263B1 (en) 2012-07-09 2019-12-25 Novartis AG Biomarkers associated with cdk inhibitors
SI2880447T1 (en) 2012-07-31 2019-09-30 Novartis Ag Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
EP2904115B1 (en) 2012-10-01 2018-08-08 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
WO2014055117A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
US20150354006A1 (en) 2012-10-19 2015-12-10 Novartis Ag Markers for acute lymphoblastic leukemia
EP2925886B1 (en) 2012-11-27 2019-04-24 Pontificia Universidad Católica de Chile Compositions and methods for diagnosing thyroid tumors
BR112015012295A8 (en) 2012-11-28 2023-03-14 Merck Sharp & Dohme USE OF A WEE1 INHIBITOR, E, KIT TO IDENTIFY A PATIENT WITH CANCER
WO2014113204A1 (en) 2013-01-17 2014-07-24 Personalis, Inc. Methods and systems for genetic analysis
EP2953970A4 (en) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc Transthyretin antibodies and uses thereof
TWI582239B (en) 2013-03-11 2017-05-11 諾華公司 Markers associated with wnt inhibitors
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
EP3404116B1 (en) 2013-03-15 2022-10-19 The University of Chicago Methods and compositions related to t-cell activity
EP2971149B1 (en) 2013-03-15 2018-05-09 Baylor Research Institute Ulcerative colitis (uc)-associated colorectal neoplasia markers
US10535420B2 (en) 2013-03-15 2020-01-14 Affymetrix, Inc. Systems and methods for probe design to detect the presence of simple and complex indels
EP2971132B1 (en) 2013-03-15 2020-05-06 Baylor Research Institute Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer
US20160091485A1 (en) 2013-04-25 2016-03-31 The Broad Institute, Inc. Markers for ezh2 inhibitors
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015031654A2 (en) 2013-08-28 2015-03-05 Cytonics Corporation Systems, compositions, and methods for transplantation and treating conditions
KR102536833B1 (en) 2013-08-28 2023-05-26 벡톤 디킨슨 앤드 컴퍼니 Massively parallel single cell analysis
EP3965111A1 (en) 2013-08-30 2022-03-09 Personalis, Inc. Methods and systems for genomic analysis
JP6111941B2 (en) * 2013-09-06 2017-04-12 日本軽金属株式会社 Biochip substrate
JP6630273B2 (en) 2013-09-09 2020-01-15 ソマロジック・インコーポレーテッド PDGF and VEGF aptamers with improved stability and their use in the treatment of PDGF and VEGF mediated diseases and disorders
US20150098940A1 (en) 2013-10-03 2015-04-09 Oklahoma Medical Research Foundation Biomarkers for Systemic Lupus Erythematosus Disease Activity, and Intensity and Flare
GB2535066A (en) 2013-10-03 2016-08-10 Personalis Inc Methods for analyzing genotypes
US20160304969A1 (en) 2013-12-17 2016-10-20 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
EP3102701A1 (en) 2014-02-07 2016-12-14 Novartis AG Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
US9153357B1 (en) * 2014-03-27 2015-10-06 Rohm And Haas Electronic Materials Llc Adhesion promoter
US9136037B1 (en) * 2014-03-27 2015-09-15 Rohm And Haas Electronic Materials Llc Adhesion promoter
WO2016008048A1 (en) 2014-07-15 2016-01-21 Ontario Institute For Cancer Research Methods and devices for predicting anthracycline treatment efficacy
US10093967B2 (en) 2014-08-12 2018-10-09 The Regents Of The University Of Michigan Detection of nucleic acids
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
EP4026913A1 (en) 2014-10-30 2022-07-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
JP6759229B2 (en) 2014-12-08 2020-09-23 バーグ エルエルシー Use of markers containing filamin A in the diagnosis and treatment of prostate cancer
RU2017123117A (en) 2014-12-09 2019-01-10 Мерк Шарп И Доум Корп. SYSTEM AND METHODS FOR PRODUCING BIOMARKERS OF GENE SIGNATURES OF RESPONSE TO PD-1 ANTAGONISTS
EP3283882B1 (en) 2015-04-17 2020-12-16 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
DK3245517T3 (en) 2015-10-07 2019-01-14 Selma Diagnostics Aps Flow system and method for digital counting
EP3362580B1 (en) 2015-10-18 2021-02-17 Affymetrix, Inc. Multiallelic genotyping of single nucleotide polymorphisms and indels
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
GB2600627B (en) 2016-05-27 2022-12-07 Personalis Inc Personalized genetic testing
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
WO2018137705A1 (en) 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof
CN110462062A (en) 2017-01-26 2019-11-15 俄克拉荷马医学研究基金会 Systemic loupus erythematosus Disease Activity, intensity and the biomarker of acute attack
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
EP3375889B1 (en) 2017-03-17 2019-12-11 HiFiBiO SAS Single cell analysis
JP2020517715A (en) 2017-04-28 2020-06-18 メルク・シャープ・エンド・ドーム・コーポレイション Biomarkers for cancer therapy
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
WO2019016772A2 (en) 2017-07-21 2019-01-24 Novartis Ag Compositions and methods to treat cancer
US11497762B2 (en) 2017-11-03 2022-11-15 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
US20200377958A1 (en) 2017-12-01 2020-12-03 Millennium Pharmaceuticals, Inc. Biomarkers and methods for treatment with nae inhibitors
WO2019213276A1 (en) 2018-05-02 2019-11-07 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
WO2020081204A1 (en) 2018-10-18 2020-04-23 Oklahoma Medical Research Foundation Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity
MX2021006234A (en) 2018-11-30 2021-09-10 Caris Mpi Inc Next-generation molecular profiling.
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
US20220162198A1 (en) 2019-04-12 2022-05-26 The Regents Of The University Of California Compositions and methods for increasing muscle mass and oxidative metabolism
KR20220015394A (en) 2019-04-30 2022-02-08 라리마 테라퓨틱스, 인코포레이티드 Frataxin sensitivity markers for determining the efficacy of prataxin replacement therapy
CN110066861A (en) * 2019-05-05 2019-07-30 南京拓远生物科技有限公司 A kind of patterning microarray flow cell, production method, detection method and its application
MX2021015058A (en) 2019-06-07 2022-04-06 Scribe Therapeutics Inc Engineered casx systems.
US20220348925A1 (en) 2019-09-09 2022-11-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of sod1
CN114729368A (en) 2019-09-09 2022-07-08 斯克里贝治疗公司 Compositions and methods for immunotherapy
IL293489A (en) 2019-12-02 2022-08-01 Caris Mpi Inc Pan-cancer platinum response predictor
CA3159316A1 (en) 2019-12-06 2021-06-10 Benjamin OAKES Compositions and methods for the targeting of rhodopsin
EP4069846A1 (en) 2019-12-07 2022-10-12 Scribe Therapeutics Inc. Compositions and methods for the targeting of htt
KR20220125332A (en) 2020-01-10 2022-09-14 스크라이브 테라퓨틱스 인크. Compositions and methods for targeting PCSK9
EP4121535A1 (en) 2020-03-18 2023-01-25 Scribe Therapeutics Inc. Compositions and methods for the targeting of c9orf72
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
EP4256054A1 (en) 2020-12-03 2023-10-11 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
WO2022120089A1 (en) 2020-12-03 2022-06-09 Scribe Therapeutics Inc. Compositions and methods for the targeting of ptbp1
WO2022216846A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
WO2022216841A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
CA3214833A1 (en) 2021-04-06 2022-10-13 Bpgbio, Inc. Protein markers for the prognosis of breast cancer progression
WO2023196937A1 (en) 2022-04-06 2023-10-12 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring frataxin replacement therapy
WO2023235818A2 (en) 2022-06-02 2023-12-07 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
WO2023240074A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
EP4314267A1 (en) 2022-06-07 2024-02-07 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007087A1 (en) * 1989-11-13 1991-05-30 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282287A (en) * 1980-01-24 1981-08-04 Giese Roger W Biochemical avidin-biotin multiple-layer system
GB8314523D0 (en) * 1983-05-25 1983-06-29 Lowe C R Diagnostic device
US4542102A (en) * 1983-07-05 1985-09-17 Molecular Diagnostics, Inc. Coupling of nucleic acids to solid support by photochemical methods
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
US4937188A (en) * 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US4762881A (en) * 1987-01-09 1988-08-09 E. I. Du Pont De Nemours And Company Photoreactive benzoylphenylalanines and related peptides
US5077085A (en) * 1987-03-06 1991-12-31 Schnur Joel M High resolution metal patterning of ultra-thin films on solid substrates
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
US5011770A (en) * 1987-09-04 1991-04-30 Molecular Devices, Inc. DNA detection method
JP2897959B2 (en) * 1988-05-20 1999-05-31 エフ.ホフマン―ラ ロシュ アクチェンゲゼルシャフト Immobilized sequence-specific probe
US5237016A (en) * 1989-01-05 1993-08-17 Siska Diagnostics, Inc. End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids
US5077210A (en) * 1989-01-13 1991-12-31 Eigler Frances S Immobilization of active agents on substrates with a silane and heterobifunctional crosslinking agent
WO1991000868A1 (en) * 1989-07-07 1991-01-24 National Research Development Corporation Immobilised polynucleotides
GB2233654A (en) * 1989-07-07 1991-01-16 Nat Res Dev Immobilised polynucleotides
PT96458B (en) * 1990-01-10 1998-06-30 Chiron Corp USE OF TRANSCRIPTS OF DNA DEPENDENT POLYMERASE RNA AS REGISTERING MOLECULES FOR SIGNAL AMPLIFICATION IN NUCLEIC ACID HYBRIDIZATION TESTS
US5324633A (en) * 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
WO1991007087A1 (en) * 1989-11-13 1991-05-30 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE, Volume 251, issued 15 February 1991, FODOR et al., "Light-Directed Spatially Addressable Parallel Chemical Synthesis", pages 767-773. *

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080585A (en) * 1994-02-01 2000-06-27 Oxford Gene Technology Limited Methods for discovering ligands
WO1995021265A1 (en) * 1994-02-01 1995-08-10 Isis Innovation Limited Methods for discovering ligands
EP0764214A1 (en) * 1994-06-08 1997-03-26 Affymax Technologies N.V. Bioarray chip reaction apparatus and its manufacture
EP0764214A4 (en) * 1994-06-08 1997-05-07
EP0913485A1 (en) * 1994-06-17 1999-05-06 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for fabricating microarrays of biological samples
EP0804731A1 (en) * 1994-06-17 1997-11-05 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for fabricating microarrays of biological samples
EP0804731A4 (en) * 1994-06-17 1997-11-26
AU709276B2 (en) * 1994-06-17 1999-08-26 Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for fabricating microarrays of biological samples
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
EP0952216A2 (en) * 1994-10-13 1999-10-27 Lynx Therapeutics, Inc. Solid phase supports with PNA and amidate tag compliments
US6138077A (en) * 1994-10-13 2000-10-24 Lynx Therapeutics, Inc. Method, apparatus and computer program product for determining a set of non-hybridizing oligonucleotides
USRE43097E1 (en) 1994-10-13 2012-01-10 Illumina, Inc. Massively parallel signature sequencing by ligation of encoded adaptors
EP2110445A3 (en) * 1994-10-13 2010-06-02 Solexa, Inc. Molecular tagging system
US5695934A (en) * 1994-10-13 1997-12-09 Lynx Therapeutics, Inc. Massively parallel sequencing of sorted polynucleotides
US5635400A (en) * 1994-10-13 1997-06-03 Spectragen, Inc. Minimally cross-hybridizing sets of oligonucleotide tags
EP0952216A3 (en) * 1994-10-13 2000-01-19 Lynx Therapeutics, Inc. Solid phase supports with PNA and amidate tag compliments
EP1724348A3 (en) * 1994-10-13 2008-10-08 Solexa, Inc. Solid phase supports with PNA and amidate tag compliments
US5604097A (en) * 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
US5863722A (en) * 1994-10-13 1999-01-26 Lynx Therapeutics, Inc. Method of sorting polynucleotides
US6140489A (en) * 1994-10-13 2000-10-31 Lynx Therapeutics, Inc. Compositions for sorting polynucleotides
USRE39793E1 (en) 1994-10-13 2007-08-21 Solexa, Inc. Compositions for sorting polynucleotides
US6172214B1 (en) 1994-10-13 2001-01-09 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US6172218B1 (en) 1994-10-13 2001-01-09 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US6235475B1 (en) 1994-10-13 2001-05-22 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US6280935B1 (en) 1994-10-13 2001-08-28 Lynx Therapeutics, Inc. Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags
EP1724348A2 (en) 1994-10-13 2006-11-22 Solexa, Inc. Molecular tagging system
US6352828B1 (en) 1994-10-13 2002-03-05 Lynx Therapeutics, Inc. Oligonucleotide tags for sorting and identification
US7138268B2 (en) 1995-03-28 2006-11-21 Agilent Technologies, Inc. Dry biochemical assay plate and method for making the same
US7083917B2 (en) 1996-02-09 2006-08-01 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US8288521B2 (en) 1996-02-09 2012-10-16 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US9234241B2 (en) 1996-02-09 2016-01-12 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP0920440A4 (en) * 1996-02-09 2004-08-25 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US9206477B2 (en) 1996-02-09 2015-12-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US8703928B2 (en) 1996-02-09 2014-04-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US8624016B2 (en) 1996-02-09 2014-01-07 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP2574617A1 (en) * 1996-02-09 2013-04-03 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP2573101A1 (en) * 1996-02-09 2013-03-27 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP2368897A1 (en) * 1996-02-09 2011-09-28 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP2332958A1 (en) * 1996-02-09 2011-06-15 Cornell Research Foundation, Inc. Detection of nucleic and sequence differences using the ligase detection reaction with addressable arrays
EP2332957A1 (en) * 1996-02-09 2011-06-15 Cornell Research Foundation, Inc. Detection of nucleic and acid sequence differences using the ligase detection reaction with addressable arrays
US7914981B2 (en) 1996-02-09 2011-03-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7893233B2 (en) 1996-02-09 2011-02-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7892747B2 (en) 1996-02-09 2011-02-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7892746B2 (en) 1996-02-09 2011-02-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7888009B2 (en) 1996-02-09 2011-02-15 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP1958955A1 (en) * 1996-02-09 2008-08-20 Cornell Research Foundation, Inc. Spatially addressable oligonucleotide arrays and method of making the same
EP0920440A2 (en) * 1996-02-09 1999-06-09 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US7166434B2 (en) 1996-05-29 2007-01-23 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US7097980B2 (en) 1996-05-29 2006-08-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US7429453B2 (en) 1996-05-29 2008-09-30 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US7364858B2 (en) 1996-05-29 2008-04-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US7332285B2 (en) 1996-05-29 2008-02-19 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US7320865B2 (en) 1996-05-29 2008-01-22 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US7312039B2 (en) 1996-05-29 2007-12-25 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5858666A (en) * 1996-08-29 1999-01-12 Biotechnology Research And Development Corporation Apparatus and method of detection employing an AC frequency sensor array
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
US8140148B2 (en) 1998-01-20 2012-03-20 Boston Scientific Scimed Ltd. Readable probe array for in vivo use
DE19853640C2 (en) * 1998-11-20 2002-01-31 Molecular Machines & Ind Gmbh Multi-vessel arrangement with improved sensitivity for optical analysis, processes for its production and its use in optical analysis processes
DE19853640A1 (en) * 1998-11-20 2000-06-08 Molecular Machines & Ind Gmbh Multi-vessel arrangement with improved sensitivity for optical analysis
US7932213B2 (en) 1999-05-11 2011-04-26 President And Fellows Of Harvard College Small molecule printing
WO2001001142A2 (en) * 1999-06-29 2001-01-04 Chiron Corporation Arrays of biopolymeric agents and method for their production and use
WO2001001142A3 (en) * 1999-06-29 2001-08-30 Chiron Corp Arrays of biopolymeric agents and method for their production and use
US7455965B2 (en) 2000-04-14 2008-11-25 Cornell Research Foundation, Inc. Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction
US8492085B2 (en) 2000-04-14 2013-07-23 Cornell Research Foundation, Inc. Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction
US9340834B2 (en) 2000-04-14 2016-05-17 Cornell Research Foundation, Inc. Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction
US9725759B2 (en) 2000-04-14 2017-08-08 Cornell Research Foundation, Inc. Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction
US10131938B2 (en) 2000-04-14 2018-11-20 Cornell Research Foundation, Inc. Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction
EP1421201A2 (en) * 2001-07-31 2004-05-26 New York Institute Of Technology Methods for immobilizing molecules to a solid phase and uses thereof
EP1421201A4 (en) * 2001-07-31 2005-11-23 New York Inst Techn Methods for immobilizing molecules to a solid phase and uses thereof
US7195872B2 (en) 2001-11-09 2007-03-27 3D Biosurfaces, Inc. High surface area substrates for microarrays and methods to make same
DE10260431B4 (en) * 2002-12-21 2006-05-04 Forschungszentrum Jülich GmbH Method for self-aligning immobilization of living cells on a silicon-based substrate
DE10260431A1 (en) * 2002-12-21 2004-07-01 Forschungszentrum Jülich GmbH Self-justifying immobilization of living cells on a silicon substrate, useful in preparation of sensors, by attaching mutually interacting molecules to surfaces of cells and substrate

Also Published As

Publication number Publication date
AU4110793A (en) 1993-11-29
US5412087A (en) 1995-05-02

Similar Documents

Publication Publication Date Title
US5412087A (en) Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
KR970001577B1 (en) Very large scale immobilized peptide synthesis
US6610482B1 (en) Support bound probes and methods of analysis using the same
US6379895B1 (en) Photolithographic and other means for manufacturing arrays
US6919211B1 (en) Polypeptide arrays
US5252743A (en) Spatially-addressable immobilization of anti-ligands on surfaces
JP2002535013A (en) Replicatable probe array
US20050064494A1 (en) Chemically modified biological molecules and methods for coupling biological molecules to solid support
JP2006227017A (en) Method for reducing non-specific binding to nucleic acid probe array
EP0502060A4 (en) Spatially-addressable immobilization of anti-ligands on surfaces
KR20010001577A (en) Process for Preparing Oligopeptidenucleotide Probe Using Polymeric Photoacid Generator
US20060194258A1 (en) Polypeptide array synthesis
JP3857075B2 (en) Reactive solid phase carrier and DNA fragment detection tool

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA